STATISTICAL ANALYSIS PLAN :MCP-103-204- SAP -01
Final Version 1.0 ,04 October 2016
Study Title: A Phase 2b, Rando mized, Double -blind, Double -dummy , Placebo 
controlled, Parallel -group, Dose -range- finding Study  of Two Del ayed 
Release Formulat ions of Linacl otide Administered Orally for 12 Weeks 
to Pati ents wi th Irritable Bowel  Syndrome wi th Const ipation
Study Number: MCP -103-204
Product Name: linaclot ide
Sponsor: Ironwood Pharmaceut icals, Inc
301 Binney  Street
Cambridge, MA 02142
Final Date: 04 October 2 016
Confidentiality Statement
The contents of this document are confident ial and belo ng to Ironwood Pharmaceut icals, Inc. 
Except as may  be otherwise agreed to in writing, by  accepting or reviewing these materials, 
you (including any  colleagues or subordi nates) agree to hold such informat ion in confidence 
and not to disclose it to others (except where required by  applicable law), nor to use it for 
unauthori zed purposes. In the event of actual or suspected breach of this obligat ion, 
Ironwood should be promptl y notified.
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 2of 86TABLE OF  CONTENTS
LIST OF ABBREVIATION S...................................................................................................... 8
1. INTRODUCTION ............................................................................................................. 10
2. STUDY OBJECTIVES ..................................................................................................... 11
3. STUDY DESIGN .............................................................................................................. 12
3.1 GENERAL DESCRIPTION .................................................................................... 12
3.2 DISCUSSION OF STUDY DESIGN, INCLUDING CH OICE OF CONTROL 
GROUPS ................................................................................................................. 12
3.3 TREATMENTS ADMINISTE RED ......................................................................... 13
3.4 METHODS OF ASS IGNING SUBJECTS TO T REATMENT GROUPS ................ 14
3.5 BLINDING .............................................................................................................. 14
4. DETERMINATION OF SAM PLE SIZE ........................................................................... 15
5. PHARMACOKINETICS, EF FICACY AND SAFETY AS SESSMENTS ......................... 16
5.1 STUDY SCHEMATIC AND SCHEDULE OF ASSESSME NT.............................. 16
5.2 PHARMACOKINETIC ASSE SSMENTS ............................................................... 20
5.3 EFFICACY ASSESSMENTS .................................................................................. 20
5.3.1 Key Efficacy Assessments .............................................................................. 20
5.3.2 Other Efficacy  Assessments ........................................................................... 21
5.3.3 Health Outcom es Assessments ....................................................................... 25
5.3.3.1 Short Form -12 Heal th Survey  Versi on 2 (SF -12v2) .............................. 25
5.3.3.2 EuroQoL -5 Dimensio n (EQ -5D- 3L)..................................................... 25
5.3.3.3 Short Form McGill Pain Questionnaire -2 (SF -MPQ -2)......................... 26
5.3.3.4 Irritable Bowel  Syndrom e-Symptom  Severi ty Scale (IBS- SSS) ............ 26
5.4 SAFETY ASSESSMENTS ...................................................................................... 26
5.4.1 Adverse Events .............................................................................................. 26
5.4.1.1 Causalit y Assessment ........................................................................... 27
5.4.1.2 Severit y Assessme nt............................................................................. 27
5.4.1.3 Serious Adverse Events ........................................................................ 27
5.4.2 Medical History ............................................................................................. 27
5.4.3 Physical Examinat ion..................................................................................... 27
5.4.4 Vital Signs ..................................................................................................... 28
5.4.5 Clinical Laboratory  Data ................................................................................ 28
6. STATISTICAL METHODS .............................................................................................. 29
6.1 GENERAL METHODS ........................................................................................... 29
6.2 ADJUSTING FOR COVARI ATES ......................................................................... 29
6.3 HANDLING OF DROPOUTS /MISSING DATA IMPUTA TION METHOD .......... 29
6.4 INTERIM ANALYSIS AND DAT A MONITORING ............................................. 30
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 3of 866.5 MULTICENTER STUDIES .................................................................................... 30
6.6 MULTIPLE COMPARISONS /MULTIPLICITY ..................................................... 30
6.7 USE OF AN EFFICACY S UBSET .......................................................................... 30
6.8 ACTIVE CONTROL TO SH OW EQUIVALENCE ................................................ 30
6.9 EXAMINATION OF SUBGR OUPS ....................................................................... 30
7. ANALYSIS METHODS ................................................................................................... 31
7.1 PATIENT POPULATIONS ..................................................................................... 31
7.1.1 Screened Population ....................................................................................... 31
7.1.2 Randomized Populat ion................................................................................. 31
7.1.3 Safety Popul ation........................................................................................... 31
7.1.4 Intent -to-Treat Popul ation.............................................................................. 31
7.2 PROTOCOL DEVIATIONS .................................................................................... 31
7.3 PATIENT DISPOSITION ....................................................................................... 32
7.4 DEMOGRAPHICS AND OTHER BASEL INE CHARACTERISTICS ................... 33
7.5 MEASUREMENT OF TREAT MENT COMPLIANCE ........................................... 33
7.6 EXTENT OF EXPOSURE ...................................................................................... 34
7.7 PRIOR AND CONCOMITANT MEDICATION ..................................................... 35
7.8 EDIARY COMPLIANCE ........................................................................................ 35
7.9 EFFICACY ANALYSIS .......................................................................................... 36
7.9.1 Key Efficacy Parameter(s) .............................................................................. 37
7.9.1.1 Analyses of the Key  Efficacy  Parameters .............................................. 38
7.9.1.2 Sensit ivity Analyses of the Key Efficacy  Parameters ............................ 39
7.9.2 Other Efficacy  parameter(s) ........................................................................... 40
7.9.2.1 Sustaine d Responders ........................................................................... 43
7.9.2.2 Analyses of Other Efficacy  Parameters ................................................. 44
7.10 POSITIVE CONTROL ............................................................................................ 45
7.11 SAFETY ANALYSIS .............................................................................................. 45
7.11.1 Adverse Events .............................................................................................. 45
7.11.2 Clinical Laboratory  Param eters ...................................................................... 47
7.11.3 Vital Signs ..................................................................................................... 49
7.11.4 Other Safet y Param eters ................................................................................. 50
7.11.4.1 Physical Examinat ion........................................................................... 50
7.12 HEALTH OUTCOMES ANAL YSIS ....................................................................... 50
7.12.1 Short Form -12 Heal th Survey  Versi on 2......................................................... 50
7.12.2 EuroQol -5 Dimensi on (EQ -5D- 3L)................................................................ 51
7.12.3 Short Form McGill Pain Questionnaire -2 (SF -MPQ -2)................................. 51
7.12.4 Irritable Bowel  Syndrom e-Symptom  Severi ty Scale (IBS- SSS) ...................... 51
8. CHANGES FROM ANALYSE S PLANNED IN THE PRO TOCOL ................................. 52
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 4of 869. DAT A HANDLING CONVENTIONS .............................................................................. 54
9.1 VISIT TIME WINDOWS F OR SAFETY ANALYSIS ............................................ 54
9.2 VISIT TIME WINDOWS F OR EFFICACY ANALYSIS ........................................ 54
9.3 POOLING OF TRIAL CENTERS ........................................................................... 56
9.4 DERIVED EFFICACY VAR IABLES ..................................................................... 56
9.4.1 Patient Recall for eDi ary Data ........................................................................ 56
9.4.2 Handling of Missing eDiary  Data ................................................................... 58
9.4.3 Weekly Stool  Frequency Rates ....................................................................... 60
9.4.3.1 Length of an Analysis Week ................................................................. 60
9.4.3.2 Weekly Stool  Frequency Rate Calculat ions.......................................... 60
9.4.3.3 Overall Weekly  Stool  Frequency Rate Calculations for Each Analysis 
Period................................................................................................... 61
9.4.4 Other Weekly  Scores Derivat ion.................................................................... 61
9.5 REPEATED OR UNSCHEDU LED ASSESSMENTS OF S AFETY 
PARAMETERS ....................................................................................................... 62
9.6 MISSING DATE OF THE LAST DOSE OF STUDY D RUG .................................. 62
9.7 MISSING SEVERITY ASS ESSMENT FOR ADVERSE EVENTS ........................ 62
9.8 MISSING RELATIONSHIP TO STUDY DRUG FOR ADVERSE EVENTS ......... 63
9.9 MISSING DAT E INFORMATION FOR AD VERSE EVENTS .............................. 63
9.10 MISSING DATE INFORMA TION FOR PRIOR OR CO NCOMITANT 
MEDICATIONS ...................................................................................................... 65
9.10.1 Incomplete Star t Date ..................................................................................... 66
9.10.2 Incomplete Stop Date ..................................................................................... 66
9.11 CHARACTER VALUES OF CLINICAL LABORATORY PARAMETERS .......... 67
9.12 HEALTH OUTCOME PARAM ETERS .................................................................. 68
9.12.1 Short Form 12 Health Survey  Versi on 2 ......................................................... 68
9.12.2 EuroQol -5 dimensi on (EQ -5D- 3L)................................................................. 71
9.12.3 Short Form McGill Pain Questionnaire -2 (SF -MPQ -2)................................. 72
9.12.4 Irritable Bowel  Syndrom e-Symptom  Severi ty Scale (IBS- SSS) ...................... 73
10. REFERENCES .................................................................................................................. 74
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 5of 86LIST OF IN -TEXT TABLES
Table 1. Treatments Administered ............................................................................... 14
Table 2. Schedule of Evaluations MCP -103-204 .......................................................... 17
Table 3. Criteria for Potenti ally Clinically Si gnificant Labora tory Resul ts................... 48
Table 4. Criteria for Potenti ally Clinically Si gnificant Vi tal Signs................................ 50
Table 5. Visit Time Windows for Safet y Analysis ........................................................ 54
Table 6. Analysis Time Windows for Efficacy  Analysis .............................................. 55
Table 7. Definit ion of Geographic Regio ns................................
.................................. 56
Table 8. Examples of Coding Special Character Values for Clinical Laboratory  
Param eters ..................................................................................................... 68
Table 9. Summary  of Form ulas f or Scoring and Transfor ming Scales .......................... 69
Table 10. 1998 General US Populat ion Means and Standard Deviat ions Used to 
Derive Short Form -12 Heal th Survey, Version 2.0, z -Scores —Acute Form ....70
Table 11. 1990 Factor Score Coefficients Used to Derive Physical Co mponent 
Summary  and Mental  Com ponent Summary  Scale Scores —Standard and 
Acute Forms .................................................................................................. 70
Table 12. EuroQol  Quali ty-of-Life Quest ionnaire Utilit y Index..................................... 72
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 6of 86LIST OF IN -TEXT FIGURES
Figure 1. Overview of Study  Design ............................................................................. 13
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 7of 86LIST OF APPENDICES
Appendix I. Bristol Stool  Form  Scale ................................................................................ 75
Appendix II. SF-12v2 ......................................................................................................... 76
Appendix III. EQ-5D- 3L Questionnaire ............................................................................... 79
Appendix IV. Short -Form McGill Pain Quest ionnaire -2....................................................... 81
Appendix V. Irritable Bowel  Syndrom e-Symptom  Severi ty Scale ....................................... 82
Appendix VI. Mixed Model  for Repeated Measures ............................................................. 84
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 8of 86LIST OF ABBREVIATION S
AE adverse event
ALT alanine aminotr ansferase
ANCOVA analysis of covariance
APC Abdo minal Pain and Const ipation
AST aspartate aminotransferase
BM bowel  movement
BP blood pressure
bpm beats per minute
BSFS Bristol Stool  Form  Scale
CBC complete bl ood count
CIC chronic idiopathic const ipation
CMH Cochran -Mantel -Haenszel
CSBM complete spontaneous bowel movement
DR delayed release
DR1 delayed release formulat ion 1 –targeted to release in ileal regio n
DR2 delayed release formulat ion 2 –targeted to release in the late ileum to 
ascend ing colon 
eCRF electroni c case report form
eDiary electroni c diary
EOT End-of-Treatm ent Peri od
EQ-5D-3L EuroQol -5 Dimensi on
HEENT head, ears, ey es, nose, throat
IBS-C Irritable Bowel  Syndrom e with Consti pation
IBS- SSS Irritable Bowel  Syndrom e –Symptom  Severit y Scale
ICF inform ed consent form
IPD Important Protocol Deviat ions
IR immediate release
ITT Intent -to-Treat
IWRS interact ive web response system
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 9of 86LLN lower limi t of norm al
LOCF last observat ion carri ed forward
LS least-squares
MCMC Mon te-Carlo Markov chain
MedDRA Medical Dict ionary for Regulatory  Activities
MI multiple imputation
MMRM Mixed Model  Repeated Measures
NRS numerical rat ing scale
OC observed case
PCS potenti ally clinically significant
PID patient identificat ion number
RM rescue m edicati on
SAE serious adverse event
SAP statist ical analysis plan
SBM spontaneous bowel movement 
SD standard deviat ion
SF-12-v2 Short Form -12 Heal th Survey  Versi on 2
SF-MPQ -2 Short Form McGill Pain Questionnaire - 2
SI Le Sy stème Intern ational d’Uni tés (Internat ional System o f Units)
SOC system  organ cl ass
TEAE treatm ent-emergent adverse event
ULN upper limit of normal
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 10of 861. INTRODUCTION
This stati stical analysis plan (SAP) provides a more techni cal and detailed elaboration of the 
statist ical analyses of the efficacy  and safet y data as outlined and/or specified in the amended 
protocol  of Study MCP -103-204-P-03 ( dated 09 October 2015 ). Specificat ions for the tabl es, 
figures, and data list ings are contained in a separate document . 
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 11of 862. STUDY O BJECTIVES
The obj ectives of this study  are to evaluate the safety , efficacy , and dose response of two 
different delayed release formulat ions of linaclot ide (DR; DR formulat ion 1 is DR1; DR 
formulation 2 is DR2) administered orally  to pati ents wi th irritable bowel  syndrom e with 
constipation (IBS -C).  
 
Document Date: 19-Oct-2016 15:05

linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 12of 863. STUDY DESIGN
3.1 GENERAL DESCRIPTION
TheMCP -103-204 study  is a mult icenter, randomized, double -blind, double -dummy, pl acebo -
controlled, parallel group, mult iple-dose, 12 -week study, consist ing of 3 distinct periods
(Screening, Pre treatment, and Treatment). The study  will en roll pat ients who have IBS -C 
diagnosed using Rome III criteria. Approximately  520 eli gible pat ients will be rando mized in 
equal proporti ons to one of 8 treatments: 30 μg, 100 μg, or 300 μg of the linaclot ide DR1 
formulation; 30 μg, 100 μg, or 300 μg of the linaclotide DR2 formulation; 290 μg of the IR 
formulation of linaclotide (stated as linaclot ide IR throughout); or placebo .  
 
 
 
The l ength of this trialis14-18 weeks, with 3 distinct periods, including up to 21 days of 
Screening , 14 to 21 days of Pretreatm ent, and 12 weeks of double -blind treatment. Signed 
inform ed consent from  the pati ent or the pati ent’s legally authorized representativ e will  be 
obtained before any study -related procedures beg in. During the Pretreatment Period , pati ents will  
provi de daily informat ion on bowel  habi t
s, symptom severit y,and use of Rescue Medicine . 
Patients m eeting all of the entry  criteria for this trial  at the end of the Pretreatment Period will 
enter the Treatment Period.
3.2 DISCUSSION OF STUDY DESIGN, INCLUDING CHOICE OF 
CONTROL G ROUPS
A double -blind, pl acebo -controlled, parallel -group study  design was chosen in accordance with 
the concepts in ICH E10, Ch oice of Control  Groups and Related Issues in Clinical Trials, in 
order to provide co mparable treatment groups and minimal chance of select ion or invest igator 
bias. Linaclot ide IR at the 290 μg dose (the FDA -approved dose for IBS -C) is being included in 
thestudy  as a posi tive control , against which the safet y and efficacy of the various doses of the 
two test (DR) formulat ions can be compared; to maintain the blind (linaclot ide IR is supplied as 
Document Date: 19-Oct-2016 15:05

linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 13of 86a capsule and both linaclot ide DR formulat ions are supplied as tablets), a double -dummy  design 
was emplo yed. The study  has a 14 -to 21 -day Pretreatm ent Peri od to establish a baseline without 
therapy  and to familiarize patients with data collection methodology  (i.e., electronic diary 
[eDiary]), and a 12 -week Treatment Period to compare the test treatment to the placebo control 
andthe active control ,Linaclot ide IR 290 ug (See Figure 1).
Figure 1. Overview of Study Design
Note: there is no Day 0.
*App licable to a subset of patients
**This visit represents the end of the study
3.3 TREATMENTS ADMINISTERED
Patients will  be instructed to take one tablet and one capsule in the morning at least 30 minutes 
before breakfast .Study  drug in the form of oral tablets and oral capsules will be provided by 
Ironwood or designee. For the double -blind Treatment Period, study  drug will  be administered in 
a doubl e dummy manner as described in Table 1:
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 14of 86Table 1. Treatments Administered
Treat ment Group Capsule Tablet
30 μglinaclotide DR1 Placebo 30 μglinaclotide DR1
100 μglinaclotide DR1 Placebo 100 μglinaclotide DR1
300 μglinaclotide DR1 Placebo 300 μglinaclotide DR1
30 μglinaclotide DR2 Placebo 30 μglinaclotide DR2
100 μglinaclotide DR2 Placebo 100 μglinac lotide DR2
300 μglinaclotide DR2 Placebo 300 μglinaclotide DR2
290 μglinaclotide IR 290 μglinaclotide IR Placebo
Placebo Placebo Placebo
Oral capsule and oral tablet both administered once daily in the morning at least 30 minutes before 
breakfast
3.4 METHODS OF ASSIGNING SUBJECTS TO TREATMENT GROUPS
Patients who m eet all of the inclusio n criteria and none of the exclusio n criteria will be 
rando mized into the study  at the Rando mizat ion Visit on Day  1. Approximately  520 pati ents will 
be randomized in eq ual proporti ons to one of eight treatments (described in Sect ion 3.3). 
Randomization numbers will be assigned by interactive web response system (IWRS).
3.5 BLINDING
This study  is a doubl e-blind, double -dummy  study .
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 15of 864. DETERMINATION OF SAM PLE SIZE
The sample size per treatment group was determined based on a one -way design and includes 8 
treatm ents: placebo; 30 µg, 100 µg, or 300 µg of the linaclot ide DR1 formulat ion; 30 µg, 100 µg, 
or 300 µg of the linaclotide DR2 form ulation; and the 290 µg dose of the linaclot ide IR 
formulation(the FDA -approved dose for IBS -C). Previous trials wit h linaclot ide IR 
demonstrated treatm ent differences with respect to Change fro m Baseline in 12- Week 
Abdo minal Pain of 0.78 ( -1.196 vs. -1.975 for placebo and linaclotide IR, respectively), and a 
standard deviat ionof 1.73 (based on the root mean squared error from an ANCOVA adjust ing 
for baseline pain). Based on these historical values, it was estimated that, within each 
formulation, the highest two active treatment arms (DR1 100 µg and 300 µg; DR2 100 µg and 
300 µg) woul d reflect the previously  observed Change fro m Baseline (-1.975), the lowest active 
treatm ent arm s withineach f ormulation (DR1 30 µg; DR2 30 µg) would achieve a Change from 
Baseline of -1.586 reflect ing50% of  the observed prior treatment difference ( -0.39 ), and placebo 
woul d reflect the previously observed Change from Baseline (-1.196). Under these assumpt ions, 
a study  with 65 patients per treatm ent arm  (520 total patients) wi ll have 81% power based on a 
2-sided linear trends test within each formulat ion (linear contrast: -3 (placebo) -1 (30 µg) 
1(100 µg) 3 (300 µg); IR formulat ion not included) at an alpha level of 0.05. In addition, 
subsequent pairwise co mpar ison between pla cebo and the active treatment groups reflecting the 
previously observed treatment difference will have 73% statist ical power (two -sided, α = 0.05).
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 16of 865. PHARMACOKINETICS, EF FICACY AND SAFETY 
ASSESSMENTS
5.1 STUDY SCH EMATIC AND SCHEDULE OF ASSESSMENT
The schedule of evaluat ions for Study  MCP-103-204 is presented in Table 2.  The double -blind 
treatm ent peri od starts wi th the first dose of double -blind study  drug and ends wit h the last 
assessment.
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 17of 86Table 2. Schedule of Evaluations MCP - 103-204
Screening 
Period
(Up to 21 
days)Pretreatment 
Period
(14 to 21 
days)Treat ment Period
(12 weeks)
Visit Days →Screening 
Visit
(Day -42 
through 
Day -15)Pretreatment 
Visit
(Day -21 to 
Day -14)Randomization 
Visit
(Day 1)Follow-up 
Call
(Day 3)Week 4 Visit
(Day 29±3)Week 8 Visit
(Day 57±3)Week 12/End -of-
Treat ment Period 
Visit o
(Day 85+3)
Visit Numbers → Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Study Procedure ↓
Signature of ICF X
Inclusion and Exclusion 
Criteria VerificationX X X
IWRS RegistrationaX X X X X X
Medical History X
Physical ExaminationbX X
Body Weight and HeightcX X X X X X
Seated Vital SignsdX X X X X X
Prior and Concomitant 
Medicinese X X X X X X
Clinical Laboratory Tests fX X X
Pregnancy TestgX X X
Laxative/Suppository/Enema 
Washout Instructions h X
AE EvaluationsiX X X X X X
eDiaryRegistration and 
Trainingj X X X X X
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 18of 86Table 2. Schedule of Evaluations MCP - 103-204
Screening 
Period
(Up to 21 
days)Pretreatment 
Period
(14 to 21 
days)Treat ment Period
(12 weeks)
Visit Days →Screening 
Visit
(Day -42 
through 
Day -15)Pretreatment 
Visit
(Day -21 to 
Day -14)Randomization 
Visit
(Day 1)Follow-up 
Call
(Day 3)Week 4 Visit
(Day 29±3)Week 8 Visit
(Day 57±3)Week 12/End -of-
Treat ment Period 
Visit o
(Day 85+3)
Visit Numbers → Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Study Procedure ↓
Daily and Weekly 
Assessments k X X X X X
eDiaryCompliance 
Verification and Reminderl X X X X
Rescue Medicine Dispen sed mX X X X
Patient eDiaryEntry, in Clinic X X X X
Randomization X
SF-12v2 X X X X
EQ-5D-3L X X X X
SF-MPQ -2 X X X X
IBS-SSS X X
Treatment Satisfaction 
AssessmentX X X
Study Drug Dispensed X X X
Study Drug AdministrationnX
Study Drug Accountability X X X
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 19of 86AE = adverse event; BM = bowel movement; CIC = chronic idiopathic constipation; CBC = complete blood count ; EQ-5D-3L= EuroQoL -5 Dimension; IBS-
SSS = Irritable Bowel Syndrome –Symptom Severity Scale; ICF = informed consent form; SF-12-v2 = Short Form -12 Health Survey version 2; SF -MPQ -2 = 
Short Form McGill Pain Questionnaire -2
a.Site personnel will interact wi th IWRS to register the patient visit . Refer to the IWRS User Manual.
b.A phy sical examination includes the following:  general appearance, HEENT (head, ears, eyes, nose, and throat), neck, cardiov ascular, thorax/lungs, breasts, 
abdomen, rectal, genitourinar y, musculoskeletal, lymph nodes, skin, neurologic, and mental status. A rectal examination should be performed during the 
Screening Period on all patients who do not require a colonoscopy. After the Screening Period, the rectal examination is opti onal and may be performed at 
the discretion of the investigator.  Breast and genitourinary examinations are optional at the discretion of the investigator .
c.Height is measured only at the Screening Visit.
d.Vital signs must be obtained in the seated position and inclu de oral temperature, respiratory rate, blood pressure, and pulse.
e.At the Screening Visit, information related to concomitant medicine that patients are taking on the day of the visit will be captured as well as their history of 
using particular treatment s for IBS-C and CIC .
f.Chemistry, CBC, and drug screen. The urine drug screen will be performed at the Screening Visit only.
g.To be eligible to continue in the study, a negative serum pregnancy test must be documented at the Screening Visit. A negativ e urine pr egnancy test must be 
documented at the Randomization Visit (prior to dosing), and a negative serum pregnancy test must be documented at the Week 12/ End-of-Treatment Period 
(EOT) Visit.
h.Study coordinator will instruct patients about the use of laxatives, su ppositories, and enemas .
i.All AEs occurring after the patient signs the ICF will be captured. Appropriate site personnel will complete a follow -
up pho ne call to patients within 48 
hours following initial study drug administration to assess for developing AE s. The Sponsor will perform a blinded review of the safety information obtained 
from the first 40 follow -up pho ne calls, and determine whether follow -up phone calls to patients should continue or be discontinued. 
j.At the Pretreatment Visit and all subseque nt visits, the study coordinator will register the patient visit to the clinic in the patient’s eDiary . At the Pretreatment 
Visit, the study coordinator will instruct the patients about the use of the eDiary .Refer to the eDiary User Manual.
k. An eDiary willbe used for recording Daily BM-related Symptom Severity Assessments, Daily abdominal Symptom -severity  Assessments, Weekly 
Assessments, EQ -5D-3L , Treatment Satisfaction Assessment, SF -MPQ -2, SF -12-v2, IBS-SSS, and any use of rescue medicine. Patients will enter BMs and 
rescue medicine in the eDiary on an event -driven basis, and will complete an evening entry each day to record daily assessments.
l.At the Randomization Visit and all subsequent visits , the study  coordinator will review the eDiary entry  informat ion to verify  patient compliance with the 
daily  eDiary completion requirement. After determining the patient’s compliance, the study coordinator will remind patients to complete th e eDiary daily
(except at the EOT visit) . (eDiary questions may be found in the eDiary User Manual.)
m.Rescue Medicine (oral bisacodyl or bisacodyl suppositories) will be supplied to patients at the Pretreatment Visit and, if ne eded, at subsequent study drug 
dispensing visits.
n.Study drug will be administered in the clinic at the Ran domization Visit (study drug does not need to be taken in the morning before breakfast). Patients are 
instructed to fast for 2 hours before this clinic visit. On all other days, study drug will be taken once daily in the mornin g at least 30 minutes before breakfast.
o.Patients who are randomized but do not complete the Treatment Period (withdraw consent or are discontinued before they have c ompleted 12 weeks of 
treatment), will be considered Treatment Period withdrawals and should complete the procedures requ ired at the EOT Visit (even if out of window).
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 20of 865.2 PHARMACOKINETIC ASSESSMENTS
There are no pharmacokinet ic assessments planned for this study.
5.3 EFFICACY ASSESSMENTS
5.3.1 Key Efficacy Assessments
The key  efficacy  assessments that will be used to determine the key efficacy  parameters are the 
eDiaryquest ions that determine whether a bowel  movement (BM)is a complete spontaneous 
BM ( CSBM )and the daily pat ient assessment of Abdo minal Pain at its Worst:
Complete Spontaneous Bowel Movement
•BMday and time. Pati ents wi ll report BMs on an event -driven basis. An evening report will 
ask whether the patient entered all BMs for that day, and co llect BMs not previously entered 
for that day . 
•Associ ationwith a sense of com plete evacuat ion. This is assessed by the patient answ ering 
the following eDiary questi on for each BM:
“Did you feel like y ou com pletely  empt ied your bowels after your bowel  movement ?”
1=Yes
2=No
•Day of any Rescue Medicine Use . Pati ents will report rescue medicine use on an event-
driven basis. An evening repo rt will ask whether the patient entered all rescue medicine use 
for that day , and collect rescue m edicine not previously entered for that day .  
Each day  of the Pretreatment and Treatment Periods, the patient will co mplete eDiaryentrieson 
an event -drive n basis to report BMs , and whether the BM was associated with a sense of 
complete evacuat ion. (The patient is also asked to provide assessments of stool consistency and 
straining .) The pati ent will also complete eDiaryentries on an event -driven basis to r eport use of
Rescue Medicines (e.g., oral bisacodyl; bisacodyl supposi tory), laxatives, suppositories, or 
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 21of 86enemasto treat their symptoms. Patients will co mplete a daily evening report to enter any  BMs 
and Rescue Medicine usage not previously  reported by  the pat ient for that day .  
Daily Patient Assessment of Abdominal Pain at its Worst
Patient assessment of abdo minal pain at its worst will be co llected via a daily evening report in
the eDiary. The rating of abdominal pain at its worst during the previous 24 hours on a n 11- point 
numeric alrating scale ( NRS )will be provided by the pat ient answering the fo llowing quest ion:
“How woul d you rate y our worstabdominal pain in the past 24 hours?
<eDiary presents NRS where 0 is anchored with “No abdominal pain” and 10 is anchored wi th 
“Worst possible abdo minal pain” >
5.3.2 Other Efficacy Assessments
In addit ion to the key  efficacy assessments, the fo llowing efficacy assessments are used in 
determining the other efficacy  parameters.
Spontaneous Bowel Movement (SBM)
The SBM assessment i s based on the eDiary quest ions that determine whether a BM is an SBM:
•BMday and time
•Day of any Rescue Medicine Use
Stool Consistency
Patient assessment of stool consistency will be collected using two questions by daily eDiary
entry on an event -driven basis . For each BM, the pati ent assesses his/her stool  using the Bristol  
Stool  Form  Scale ( BSFS ;Appendix I )which depicts the stool  consistency characterist ics along 
with descript ions for each of t hem. The patient assign sa corresponding score for each BM. 
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 22of 86The 7 -point ordinal BSFS scale is provided below:
“Please describe the form of your stool using the following scale where: ”
1=Separate hard lumps like nuts (difficult to pass)
2=Like a sausage but lumpy 
3=Like a sausage but with cracks on the surface
4=Like a sausage or snake, smooth and soft
5=Soft pieces with clear -cut edges ( easy to pass )
6=Fluffy pieces with ragged edges, a mushy stool
7=Watery , no solid pieces (ent irely liquid)
Second, the patient assesses his/her stool using a 5-point ordi nal scale:
“How woul d you describe the consistency  of your stool?”
 Very  hard
 Hard
 Neither too hard nor too soft
 Loose but not watery
 Very  loose and watery
Straining
Patient assessment of straining will b e collected daily  by eDiary entry . For each BM, degree of 
straining will be assessed by the patient using the following 5 -point ordinal scale:
“How m uch di d you strain during yourbowel  movem ent?”
1=Not at all
2=A little (mild straining)
3=A fair amount (moderate straining)
4=A large amount (severe straining)
5=An extrem e am ount (extremely severe straining)
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 23of 86Daily Patient Assessment of Abdominal Discomfort at its Worst
Patient assessment of abdo minal disco mfort at i ts worst will be collected via a daily  even ing 
report inthe eDiary. The rating of abdominal discomfort at its worst during the previous 24 
hours on a n 11- point NRS will be provided by the patient answering the fo llowing question:
“How woul d you rate yourworstabdominal discomfort in the past 24 h ours? ”  
<eDiarypresents 
NRS where 0 is anchored with “No abdo minal discomfort” and 10 is anchored with “Worst 
possible abdominal disco mfort”>
Daily Patient Assessment of Abdominal Bloating at its Worst
Patient assessment of abdo minal bloat ing at its worst will be co llected via a daily  evening report 
in the eDiary . The rating of abdominal bloat ing at its worst during the previous 24 hours on a n
11-point NRS will be provided by the pat ient answering the fo llowing quest ion:
“How woul d you rate y our worstabdo minal bloating in the past 24 hours? ”
<eDiarypresents NRS where 0 is anchored with “No abdominal bloat ing” and 10 is anchored 
with “Worst possible abdominal bloat ing”>
Weekly Patient Assessment of Constipation Severity
Patient assessment of const ipation severit y will be reported weekly by  eDiary entry . The rati ng 
of const ipation severit y during the previous 7 day s on a 5 -point ordinal scale will be provided by 
the pati ent answering the fo llowing quest ion: 
“On average, how would y ou rate y our const ipationduring the past 7 day s?”
1=None
2=Mild
3=Moderate
4=Severe
5=Very  severe
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 24of 86Weekly Patient Assessment of IBS Symptom Severity
Patient assessment of IBS symptom severit y will be reported weekly by  eDiary entry . The rating 
of IBS symptom  severi ty during the pr evious 7 days on a 5- point ordinal scale will be provided 
by the patient answering the fo llowing question: 
“On average, how would y ou rate y our IBS symptom s during the past 7 days?”
1=None
2=Mild
3=Moderate
4=Severe
5=Very  severe
Weekly Patient Assessmen t of Adequate Relief
Patient assessment of adequate relief o f IBS symptom s will  be reported weekly by  eDiary entry . 
The rating of the adequate relief during the previous 7 day s on a binary  scale will be provi ded by  
the pati ent answering the fo llowing quest ion:
“Overall, have y ou had adequate relief from y our IBS symptom s during the past 7 day s?”
1=Yes
2=No
Treatment Satisfaction Assessment
A treatment satisfact ion assessment will be performed at the Week 4Visit and all  subsequent 
study  visitsby eDiary entry. Pati ents will answer the fo llowing quest ion on a 5 -point ordinal 
scale:
“Overall, how satisfied are y ou wi th the study  medicat ion’s abilit y to relieve y our IBS 
symptoms?”
1=Not at all sat isfied
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 25of 862=A little satisfied
3=Moderately  satisfied
4=Qui te satis fied
5=Very  satisfied
5.3.3 Health Outcomes Assessments
5.3.3.1 Short Form -12 Health Survey Version 2 ( SF-12v2 )
The SF -12v2 Health Survey (1) is a widely used generic measure of healt h status ( Appendix II). 
The SF -12v2 measures eight concepts commonly represented in widely  used surveys: physical 
funct ioning, role limitat ions due to physical health problems, bodily  pain, general  health, vitality 
(energy/fat igue), social funct ioning, role limitat ions due to emotional problems, and m ental  
healt h (psycho logical distress and psychol ogical well -being). These eight scales are aggregated 
into two summary  measures: the Physical and Mental Co mponent Summary Scores. The 
SF-12v2 will be self- administered at the Rando mization Visit prior t o the patient receiving study  
drug and at all subsequent study  visits. Treatm ent Peri od wi thdrawals shoul d com plete the self -
administration of the SF -12v2 at the EOT Visit (even if out of window).
5.3.3.2 EuroQoL -5 Dimension ( EQ-5D-3L)
The EQ -5D-3L is a generic m easure of healt h status that is widely used in Europe ( Appendix 
III)(2). The descript ivesystem  consists of five questi ons assessing the following dimensio ns: 
mobility, self-care, usual  activities, pain/disco mfort, and anxiet y/depressi on. Responses to the 
five quest ions define a healt h state for which a utility  index can be derived fro m publi shed 
algorithms. (3)The second compo nent of the EQ -5D- 3Lis a visual analogue scale, asking 
patients to rate thei r healt h from 0 to 100 (0 represents worst imaginable health state and 100 
represents best imaginable healt h state). The EQ -5D-3Lwill be self -administered at the 
Randomization Vi sit prior to the pati ent receiving study  drug and at all subsequent study  visit s. 
Treatment Period withdrawals should co mplete the self -administration of the EQ -5D at the EOT 
Visit (even if out of window).
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 26of 865.3.3.3 Short Form McGill Pain Questionnaire -2 (SF-MPQ -2)
The SF -MPQ -2 is a measure that provides a comprehensive evaluat ion of both neuropathic and 
non
-neuropathic pain through assessment of 22 words describing different qualit ies of pain and 
related symptom s (Appendix IV ) (4). It will be self -administered at the Rando mizat ion Visit 
prior to the pati ent receiving study  drug and at all subsequent study  visit s. Treatm ent Peri od 
withdrawals shoul dcomplete the self -administration of the SF -MPQ -2 at the EOT Visit (even if 
out of window). T he SF -MPQ -
2 consists of a total  pain score and four summary scales: (1) 
continuous descriptors, (2) intermittent descriptors, (3) neuropathic descriptors, and (4) affect ive 
descriptors.
5.3.3.4 Irritable Bowel Syndrome -Symptom Severity Scale (IBS -SSS)
The Irri table Bowel  Syndrom e-Symptom  Severi ty Scal e (IBS -SSS, Appendix V ) (5) contains 
seven quest ions that ask patients to rate t he severit y and frequency of their abdo minal pain , the 
severit y of their abdominal distent ion, the dissat isfaction wi th their bowel  habits, and how much 
abdo minal pain or disco mfort or al tered bowel  habits interfere wi th their life in general . The IBS -
SSS will be self -administered at the Rando mizat ion Visit prior to the patient receiving study  drug 
and at the Week 4 V isit.
5.4 SAFETY ASSESSMENTS
The safet y param eters will  include adverse events (AEs), clinical laboratory  and vi tal sign 
param eters, and physical examinat ion.
5.4.1 Adverse Events
The AE assessment (interview) will be co llected from the time the patient signed the informed 
consent form unt il 30days after the patient’s last study  visit.
Document Date: 19-Oct-2016 15:05
linaclotide  Ironwood Pharmaceuticals, Inc. 
Statistical Analysis Plan: MCP-103-204-SAP-01  04 October 2016 
 
Confidential Page 27 of 86 5.4.1.1 Causality Assessment 
Causal relationship must be assessed according to the following scale: 
• Related An event where there is a reasonable possibility of a causal relationship 
between the event and the study drug 
• Unrelated Any other event 
 
5.4.1.2 Severity Assessment 
Severity will be assessed according to the following scale: 
• Mild The AE was an annoyance to the patien t but did not further hinder baseline 
functioning 
• Moderate The AE caused the patient to experience some discomfort or some interference with norma l activities but was not  hazardous to health; 
prescription drug therapy may have been employed to treat the AE 
• Severe The AE caused the patient to experien ce severe discomfort or severely 
limited or prevented normal activities and represented a definite hazard to 
health; prescription drug therapy and/ or hospitalization may have been 
employed to treat the AE 
 
5.4.1.3 Serious Adverse Events 
All adverse events will be categorized as Se rious (as defined in the MCP-103-204 Protocol, 
Section 5.5.3.2) or Non-Serious. 
5.4.2 Medical History 
A complete medical history will be performed as defined in the Schedule of Assessments 
(Table 2 ). 
5.4.3 Physical Examination 
A complete physical examination will be perfor med as defined in the Schedule of Events 
(Table 2 ). A physical examination will include the following assessments: general appearance; 
head, ears, eyes, nose, and throat (HEENT); neck; cardiovascular; thorax/lungs; abdomen; 
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 28of 86musculoskeletal; lymph nodes; skin; neurologic; and mental status. Breast, genitourinary, and 
rectal examinat ions (if required).
5.4.4 Vital Signs
Vital sign m easurements will be performed as defined in the Schedule of Events ( Table 2). Vital 
sign measurem ents include oral  temperature (°C), respiratory  rate, systoli c and diastolic blood 
pressure (BP), and pulse. Respiratory  rate, pulse, and BP readings will be taken after the patient 
has been seated for at least 5 minutes.
5.4.5 Clinical Laboratory Data
Fasted b
lood and urine samples for clinical laboratory  tests will be c ollected at the day s and 
times de fined in the Schedule o f Events (Table 2). A central  laboratory  will be used to evaluate 
all blood and urine samples (except the urine pregnancy test) . 
The fo llowing clinical labor atory  tests will  be perform ed:
•Hematology :Abso lute and different ial whi te blood cell  count, ery throcyte coun t, 
hemoglo bin, hematocrit, platelet count, and red blood cell indices (mean corpuscular vo lume, 
mean corpuscular hemoglobin, and mean corpuscular h emoglobin concentrati on)
•Chemistry :Sodium, magnesium, potassi um, calcium , chloride, gl ucose, bl ood urea ni trogen, 
creatinine, total protein, alkaline phosphatase, albumin, total bilirubin, aspartate 
aminotransferase, alanine aminotransferase, bicarbonate, phosphate, and cho lesterol
•Other :Urine drug screening (cocaine, barbiturates, amphetamines, opiates, benzodiazepine, 
alcoho l, and cannabino ids) (screening only). Clinical significance of a posit ive urine drug 
screen will be assessed by the investigator; positive resul ts for cocaine, barbiturates, and 
cannabino ids are exclusionary .
•Pregnancy test:Serum human chorionic gonadotropin pregnancy test (for women of 
childbearing potential only ) shoul d be conducted at the Screening Visit and other visit s 
specifi ed in the Schedule of Evaluations. A negat ive urine pregnancy test must be 
docum ented at the Rando mization Visit for the patient to be eligible for randomizat ion and 
dosing wit h study  drug. Posi tive results on the pregnancy test will exclude a pat ient from
participat ing or continuing in the study.
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 29of 866. STATISTICAL METHODS
6.1 GENERAL METHODS
All summaries will be presented by  treatm ent unl ess specified otherwise. Descript ive statist ics 
including the number of patients , mean, standard deviat ion(SD) , median, minimum, and 
maximum will be calculated for continuous variables. Frequencies and percentages for each 
category  will be calculated for categorical variables. Percentages will be based on the total 
number of non -missing values. The number missing will be presented, but without a percentage. 
All hypothesis tests will be two -sided wit h a 5% significance level, and 95% confidence intervals 
will be used, unless stated otherwise .  There i s no adj ustm ent for multiplicity; p-values will be 
reported as nominal .  
All statistical analyses will be performed using SAS Version 9.3 (or later) for Windows.
6.2 ADJUSTING FOR COVARIATES
As a general approach, the baseline values will be included in the mixed model repeated 
measures ( MMRM )or analysis of covariance ( ANCOVA )when the abso lute or change score are 
analyzed.  Heterogeneit y of slopes will be expl ored (e.g., revi ew of residuals, inclusio n of an 
interact ion term , com parison of group differences at the 25thand 75thpercent iles) and ,if any 
changes to planned analyses are needed, the change will be documented in the clinical study  
report.
6.3 HANDLING OF DROPOUTS /MISSING DATA IMPUTA TION METHOD
For responder endpo ints, a patient will be deemed a weekly non -responder for all weeks 
following the patient’s discontinuation fro m the study . The responder definit ion will be applied 
to the week the patient discontinues.   Unless stated otherwise, missing data will not be imputed.
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 30of 866.4 INTERIM ANALYSIS AND DATA MONITORING
No formal interim analyses are pl anned to com pare treatment groups with respec t to efficacy or 
safet y prior to f ormal com pletion of the trial.
6.5 MULTICENTER STUDIES
This study  is being conducted in approximate ly80 centers .  Due to the potential of small 
numbers of pat ients per center, data will be pool ed by  center into the following 5 geographi c
regions (as listed in Table 7): Northeast, Southeast, Midwest, Southwest, and West. 
All analyses u sing tri al center will use thi s 5
-category  geographi c regi on variable.
6.6 MULTIPLE COMPARISONS /MULTIPLICI TY
No m ultiple com parison adjust ments are planned for this study .
6.7 USE OF AN EFFICACY S UBSET
Not applicable
6.8 ACTIVE CONTROL TO SHOW EQUIVALENCE
Not applicable
6.9 EXAMINATION OF SUBGROUPS
No subgroup analyses areplanned for this study .
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 31of 867. ANALYSIS METHODS
7.1 PATIENT POPULATIONS
7.1.1 Screened Population
The Screened Populat ion consist sof all patients who signed informed consent and received a 
patient identificat ion (PID)number.
7.1.2 Randomized Population
The Rando mized Populat ion consist sof all pat ients in the Screened Popul ation who were 
rando mized to a treatment group in the study.
7.1.3 Safety Population
The Safet y Popul ation consists of all pat ients who received at least one dose of study  drug, in 
which pat ients are evaluated according to the treatment they  actually received.   The ‘treatment 
actually received’ for patients who received treatment(s) other than their rando mized treatment 
during the course of the trial will be defined as the treatment group in which the patient actually 
took the greatest number of doses.  All safet y analyses will be based on the Safet y popul ation.
7.1.4 Intent -to-Treat Population
The Intent -to-Treat (ITT) Populat ion consists of all rando mized pat ients who received at least 
one dose of study  drug. Efficacy  analysis will  be based on the ITT popul ation, in w hich patients 
are evaluated according to the treatment group to which they were assigned at randomizat ion.
7.2 PROTOCOL DEVIATIONS
Protocol  deviat ions and Important Protocol Deviat ions (IPD) will be ident ified and documented 
for all randomized pat ients prior t o unblinding through programmat ic checks o f the study  data 
Document Date: 19-Oct-2016 15:05
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 32of 86and select individual data reviews. IPDs will be determined based on review of all protocol 
deviat ionsand protocol  deviat ion categories (i.e., Use of Disallowed Medicat ion)performed by 
members o f the Ironwood Clinical Trials team, including but not limited to the Clinical Medical 
Researcher and study  Biostati stician. Deviat ions to be reviewed include, but are not limited to:
•those who entered the study  even though they  did not sati sfy the entry  criteria; 
•those who developed withdrawal criteria during the study  but were not withdrawn; 
•those who received the wrong treatment or incorrect dose; 
•those who received an excluded concomitant treatment. 
The number and percentage of subjects with IPDs will be presented by study  treatm ent and IPD 
category .Protocol deviat ions and IPDs will be provided by patientin data list ings.
7.3 PATIENT DISPOSITION
The number and percentage of patients in cluded in each of the Rando mized, Safety, and ITT
popul ationswill be summarized overall and by treatment group for each trialcenter wi thin each 
geographi c regi on. The number of pati ents in the Screened Popul ation will be summarized 
overall only by  study  center wi thin geographic region (See Section 9.3for definit ion of 
geographi c regi on).
The number and percentage of screen failure patients (i.e., patients who entered the Screening 
Period but not the Pretreatment Period) and the number and percentage of pretreatm ent failures
(i.e., pati ents who entered the Pretreatment Period but were not randomly assigned to treatment ), 
along wi th the associ ated reasons for failure, will be tabulated overall for the Screened 
Popul ation. Pati ents who init ially failed screening and were re -screened will only be counted 
once, that is, the PID used for the rescreened subject will be summarized and listed for patient 
disposi tion. 
The number and percentage of rando mized pat ients who are in the ITT populat ion, the num ber 
and percentage of patients who com plete dthe Treatm entPeriod, as well as the number and 
percentage of patients who prematurely discont inued treatment will be presented for each 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 33of 86treatm ent group and pooled across treatment groups for the Rando mized Populat ion. The reasons
for prem ature discont inuat ion from the Treatment Period as recorded on the trial com pletion 
formsof the el ectroni c case report forms (eCRFs) will be summarized (number and percentage) 
by treatment group for the Rando mized Populat ion. The number and percentage of pat ients who 
prem aturely  discontinued treatm ent will be summari zed for each treatment group by  time of 
discontinuat ion, defined as the number of days from first dose of study  drug to the date of last 
dose during the Treatment Period , categorized into weeks (W eek 1 through Week 12) . All
patients who prem aturely discont inue during the T reatm ent Period will be listed by 
discontinuat ion reason for the Randomized Population.
7.4 DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS
Dem ographic parameters (age; age group; ra ce; ethnicit y; sex; weight; height; and body  mass 
index, calculated as weight [kg]/(height [m])2)will be summarized descript ively by treatment 
group for the Safet yand ITT popul ations. Baseline efficacy parameters (including SBM 
frequency , CSBM f requency, abdo minal pain, abdominal bloat ing, abdo minal disco mfort, 
abdo minal symptom composite score [consisting of abdo minal pain, abdo minal bloat ing, 
abdo minal disco mfort], stool consistency, and straining )will be summarized descript ively by 
treatm ent group for the ITT populat ion.Continuous variables will be summarized by number of 
patients and mean, SD, median, minimum, and maximum values. Categorical variables will be 
summarized by  number and percentage of patients.
Abnorm alities in pat ients’ medical and surg ical histori es will be coded using the Medical 
Dictionary for Regulatory  Activities(MedDRA ), versi on 18.0.The number and percentage of
patients wi th abnorm alities in medical and surgical histories in each system organ class (SOC)
and preferred term will be summarized by treatment group for the Safet y Popul ation.
7.5 MEASUREMENT OF 
TREATMENT COMPLIANCE
Patients will  take thei r initial dose of study  drug at the trial center during the Rando mizat ion 
Visit (Visi t 3). For all days in the Treatm ent Peri od, pati ents are instructed to take study  drug 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 34of 86once daily  in the m orning at l east 30 minutes before breakfast.  The double -dummy dosing 
requi res all pat ients to take one capsule and one tablet for each dose.
Dosing co mpliance for the Treatment Period is defined as the number of capsules and tabl ets 
(Total  number of capsules + Total number of tablets) actually taken by a patient during the 
Treatment Period divided by the number of capsules and tablets that were expected to be taken 
during the Treatment Period mult iplied by 100. The total number of capsules actually taken will 
be calculated as total  number of capsules dispensed minus total number capsules returned minus 
total number of capsules lost.  The same calculat ion will be applied for the calculat ion of total 
tablets taken.  The total number of capsules and tablets expected to be taken during the 
Treatment Period is the number of days between the date of first dose taken and the date of last 
dose taken, inclusive, mult iplied by  2.  Patients will  be included in the periodsummary only for 
the periods they were on study  (i.e.,the periodsthat are pri or to or contain the last dose date).
This information will be obtained fro m Study  Drug Accountabilit y Record of the pati ent’s eCRF .
Descript ive statistics for study  drug compliance will be presented for the Safet y Popul ation 
by 
treatm ent group for the Treatment Period as a whole and for each of the three consecut ive drug 
dispensed/drug return periods (approximately 4-week s)comprising the Treatment Period .    
7.6 EXTENT OF EX POSURE
Exposure to study  drug for the Safet y Popul ation during the double -blind treatment period will 
be summarized by treatm ent group in terms of treatm ent durati on and calculated as the number 
of days from  the date of the first dose of double -blind study drug to the date of the last dose of 
doubl e-blind study  drug , incl usive. Overall treatment duration will also be categorized as 1 Day; 
>1 Day  to ≤ 7 Day s; >7 Days to ≤ 30 Days; >30 Day  to ≤90 Days; and ≥90 Days.  
Patient-years, defined as exposure to the study  drug in years, will be summarized by treatment
group for the Safet y Populati on.
: 19-Oct-2016 15:05
Document Date: 
 
Confidential Page 35 of 86 7.7 PRIOR AND CONCOMITANT MEDICATION 
Prior medication is defined as any medication taken before the date of the first dose of double-
blind study drug. Concomitant medi cation is defined as any medica tion taken on or after the date 
of the first dose of double-blind study drug during the Treatment Peri od. Medications started 
after the date of the last dose of double-blind study drug will not be considered concomitant 
medications. 
Both prior and concomitant medications will be coded by drug name and therapeutic class using 
WHO Drug Dictionary ve rsion B2 March 2015.  The use of pr ior and concomitant medications 
will be summarized for the Safety Population by the number and percentage of patients in each 
treatment group receiving each medication within each therapeutic class. If a patient took a 
specific medication multiple times or took multiple medications in the same category (based on 
Anatomical-Therapeutic-Chemical classification) , that patient would be counted only once for 
the coded drug name or therapeutic class. The us e of per-protocol rescue medicines is collected 
separately the eDiary and will be summarized as described in Section 7.9.2 . 
7.8 EDIARY COMPLIANCE 
Patients are required to enter thei r evening diary assessments into the eDiary each evening during 
the pretreatment and treatment period.  An even ing assessment is considered complete if all 
questions, excluding the weekly assessments, are answered. 
eDiary compliance will be calcu lated for baseline (pretreatment period), the treatment period, 
and weekly. For each time period, eDiary percen t compliance will be calculated as 100* the 
number of completed evening repo rts divided by the expected nu mber of days in the period.  
Percent compliance will also be dichotomized as ≥80% and <80% for each period, as well as the 
number and percentage of patients with > 4 / < 4 complete eDairy entries each week; these will 
be presented by treatment group for the ITT P opulation.  Descriptive statistics (number of 
patients, mean, SD, median, minimum, and maxi mum) for eDiary compliance will be presented 
for the ITT population by treatment; n and percent will be presented for the dichotomous 
categories. linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 36of 867.9 EFFICACY ANALYSIS
All efficacy analyses will be based on the ITT Populat ionfor key  efficacy  parameters . 
Daily eDiary assessments collect informat ion on BMs, including whethe r a BMis an SBM . SBM
is defined as a BM that occurs in the absence of a laxat ive, enema, or suppository use on either 
the calendar day  of the BM or the calendar day  before the BM. CSBM is defined as an SBM 
associ ated wi th a sense of co mplete evacuat ion.
Baseline values for efficacy  parameters will be derived from  the eDiarydaily data collected in 
the Pretreatment Period, specifically the period of time fro m 14days prior to the day  of 
rando mizat ion up to the time of rando mizat ion. The baseline CSBM and S BM weekly  rates will  
be derived based on the number of CSBMs and SBMs a patient had during this period. 
Baseline stool consistency  and straining will be calculated as the average of the non-missing
values from the SBMs reported by  the pati ent during this period. A patient’s baseline Stool 
Consistency and straining cannot be assessed if the patient does not have at least one SBM 
during the Pretreatment Period.  Patients with missing baseline Stool Consistency will be 
excluded fro m Stool  Consistency analyses that involve change fro m baseline.  Similarly , pati ents 
with missing baseline straining will be excluded from straining analyses that invo lve change 
from baseline.
Baseline values for patient symptom severit y parameters (e .g., abdominal disco mfort, abdomi nal 
bloat ing, abdo minal pain, 
abdominal symptom score [details provided in Sect ion7.9.2 ], and 
constipation severit y) will be the average of the non -missing severit yscores reported during this 
period.
For weekl y responder parameters based on daily  eDiaryassessments, a patient with less than 4 
complete evening reports during an analysis week will not be considered a responder for that 
week.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 37of 86Trial centers will be pooled by geographic region ( details provided in Section9.3).In lieu of trial 
center, geographic region will be used in analyses adjusting for center- to-center variabilit y.
All hypotheses will be tested at a two- sided 0.05 significance level ( Section 7.9.2 ). All 
confidence intervals will be 2-sided 95% confidence intervals, unless stated otherwise.
7.9.1 Key Efficacy Parameter (s)
There are 3 key  efficacy  parameters: 1) Weekly Change from Baseline in Abdominal Pain, 
2)Weekly Change from  Baseline in CSBM Frequency, and 3) 6/12 Week Abdominal Pain and 
Const ipation (APC) +1 Responder. The criteria for each of the 3 primary efficacy parameters are 
provi ded below:
Weekly Change from Baseline in Abdominal Pain
Abdo minal pain is measured daily using a n
11-point NRS. A patient’s weekly abdo minal pain 
score i s the average of the nonmissing abdo minal pain scores reported by  the pati ent during each 
week.
Weekly Change from Baseline in CSBM Frequency
A pat ient’s weekly CSBM frequency rate is the CSBM rate (CSBMs/week) calculated over that 
week.
6/12 Week APC +1 Responder
A 6/12 Week APC +1 Responder is a patient who meets the Weekly APC +1 Responder criteria 
for at least 6 out of the 12 weeks of the Treatment Period. 
•A Weekly APC +1 Responder is a patient who meets the criteria to be a Weekly CSBM +1 
Responder and a Weekly Abdo minal Pain Responder. If a patient did not enter informat ion 
into the eDiaryon at l east 4 days for a particular Treatment Period week, the patient will not 
be considered a Weekly  APC +1 Responder for that week.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 38of 86•AWeekly CSBM +1 Responder is a patient who has an increase from baseline o f at least 1 in 
the CSBM weekly rate for that week. If a patient did not enter informat ion into the eDiaryon 
at least 4 days for a particular Treatment Period week, the patient will not be considered a 
Weekly CSBM +1 Responder for that week.
•AWeekly Abdo minal Pain Responder is a patient who has a decrease in the weekly average 
of the abdo minal pain score of at least 30% compared w ith the baseline average.  If a patient 
did not enter informat ion into the eDiaryon at l east 4 days for a particular Treatment Period 
week, the patient will not be considered a Weekly Abdo minal Pain Responder for that week.
7.9.1.1 Analys esof the Key Efficacy P arameters
All analyses of the key  primary  efficacy endpoints will be performed on the ITT Populat ion.
For each continuous weekly change -from-baseline measure defined above, inferent ial testing of 
the change fro m baseline will be evaluated emplo ying a MMRM framework with week 
(categori cal), treatm ent, geographical regio n, and week -by-treatm ent fixed effects, and baseline 
value as a covariate. A compound symmetry covariance structure will be used to model the 
covari ance o f within-patient results. E xploratory analyses wit h unstructured and autoregressive 
(1) covariance structures will also be considered for planning purposes.
The overall dose response within each DR formulation will be conducted by  empl oying an 
overall trend test (i.e., linear contrast , see Appendix VI ) for each form ulation to test for a 
monotoni cally  increasing dose response within the MMRM .Overall treatm ent effect pairwise 
comparisons will be performed between each linaclot ide treatment and placeb o.   
 
  
Pairwise treatme nt comparisons with placebo will be performed at each week utilizing the same 
MMRM m odels.  
The efficacy analysis o f 6/12 Week APC+1 Responder rate will be performed by using a CMH 
test controlling for geographic region for each DR formulat ion (i.e., 1. D R1 and Placebo; 2. DR2 
and Placebo).  Th eoverall trend test will be assessed via the CMH correlat ion stati sticsto test for 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 39of 86a monotonically increasing dose response within the formulat ion.Pairwise com parisons between 
each linaclot ide dose and placebo wil l be performed.
7.9.1.2 Sensitivity Analyses of the Key Efficacy Parameter s
If warranted, for selected efficacy endpoints, the potential impact of missing data on the 
estimates of treatment effect will be assessed using alternative statistical methods. The follo wing 
sensit ivity analysis approach based on mult iple imputations (MI) will be utilized.
In order to characterize the extent of missing data associated with the key  efficacy  parameter, t he 
number and percentage of patients with < 4 com pleted evening diaries will be presented by 
treatm ent group for the Intent -to-treat ( ITT)Population for each week of the Treatment Period 
(Please refer to Section 7.8for addi tional details).  
Weekly data for a patient with less th an 4 com plete evening diaries will be classified as missing 
for that week.  A pattern -mixture m odel using a placebo -based mult iple imputation method ( 6) 
will be used as sensit ivity analyses to expl ore the effects of missing data on the key  efficacy 
endpo ints and select other endpoints for the ITT Populat ion.  
The pl acebo -based MI imputes missing data after dropout (monotonic) based on the placebo 
group data using mult iple imputati on m ethodol ogy f or all subjects (including active treatment 
subjects).
The st eps to implement Control -based MI are as follows:
1.Create a Monotonic Dataset :  One
-thousand (1000) datasets will be generated where 
missing outcome data at intermittent week (s) (non -monotonic) will be first imputed for 
each treatment using non -missing dat a fro m all subjects within the treatm ent group by  a 
Monte Carlo Markov Chain (MCMC) imputation model with treatment, baseline score, 
geographi c regi on and weekly  score. The MCMC statement (mcmc chain=mult iple 
impute=m onotone) in the SAS PROC MI procedure w ill be used. As a result, each of the 
1000 dataset swill only have missing ending data, or a monotone missing data pattern.
2. For each of the 1000 datasets with monotonic missing data, the monotoni c missing 
weekly data will be imputed one week at a time by a sequence o f MIs, as fo llows.  
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 40of 86Imputati on will  utilize data from  all Placebo subjects and Act ive treatment with the week 
of interest (week currently being imputed) missing.
a.For week 1, create two datasets:  one containing all placebo patients and active 
patients wi th the week 1 value -missing, referred to as Mono_imp1; one containing 
all other patients, referred to as Mono_rest1.
b.For Mono_imp1, impute the missing values at week 1 utilizing Proc MI:
PROC MI data=mono_imp1 out=reg_imp1 nimpute=1 seed=XXXX;
   By imputati on;  /*note 1000 imputation performed in step 1*/
    Var base siteid change1 ;
Run;
c.Set Mono_rest1 and reg_imp1  Call this dataset IMP1.
d.Repeat Steps 2a -2c for weeks 2 –12, respectively 
Note: for Week i, i>1, 
PROC MI data=mono_impi out=r eg_impi nimpute=1 seed=XXXX;
    By imputati on;  /*note 1000 imputation performed in step 1*/
    Var base siteid change1 change2 . . . change(i -1) change(i );
Run;
3.Analyze each of the 1000 imputed complete datasets.
a.For continuous endpo ints, perform same statist ical analyses (MMRM or ANCOVA) 
as described for observed case. 
b.For responder endpo int:
a.Using the CSBM and Abdo minal Pain data imputed above, recalculate the 
responder
b.For each imputed dataset, perform Cochran- Mantel -Haenszel (CMH) analyses 
as descr ibed above.
4.Estimat ion and Inference o f the MI datasets will be performed using Rubin’s combinat ion 
rules (7) as implemented through the MIANALYZE procedure in SAS.
7.9.2 O
ther Efficacy parameter (s)
The other efficacy parameters are as fo llows:
•Weekly CSBM +1 R esponder: For each week in the Treatment Period, a Weekly  CSBM 
+1 Responder is a patient who has an increase from baseline of at least 1 in the CSBM 
weekly rate for that week. If a patient did not enter informat ion into the eDiaryon at least 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 41of 864days for aparticular Treatment Period week, the patient will not be considered a Weekly 
CSBM +1 Responder for that week.
•6/12 Week CSBM +1 Responder :A 6/12 Week CSBM +1 Responder is a patient who 
meets the Weekly CSBM +1 Responder criteria for at least 6 out of t he 12 weeks of the 
Treatment Period. 
•9/12 Week CSBM +1 Responder :A 9/12 Week CSBM +1 Responder is a patient who 
meets the Weekly CSBM +1 Responder criteria for at least 9 out of the 12 weeks of the 
Treatment Period. 
•CSBM (SBM) within 24 Hours of Receiving the First Dose of Study Drug : Date and time 
of first dose and date and time of first CSBM (SBM) is used to determine whether a CSBM 
(SBM) is occurred within 24 hours after the patient took the first dose of study  drug.
•Change from Baseline in 12- week CSBM Frequency Rate: A patient’s 12 -week CSBM 
frequency  rate will  be the CSBM rate (CSBMs/week) calculated over the 12 weeks of the 
Treatment Period.
•Weekly Abdominal Pain Responder :AWeekly Abdo minal Pain Responder is a pat ient 
who has a decrease in the weekly average of the abdominal pain score of at least 30% 
compared wi th the baseline average.  If a patient did not enter information into the eDiaryon 
at least 4 days for a particular Treatment Period week, the patient will not be considered a 
Weekly A bdominal Pain Responder for that week.
•6/12 Week Abdominal Pain Responder :A 6/12 Week Abdo minal Pain Responder is a 
patient who m eets the Weekly Abdominal Pain Responder criteria for at least 6 out of the 12 
weeks of the Treatment Period.
•9/12 Week Abdomi nal Pain Responder :A 9/12 Week Abdo minal Pain Responder is a 
patient who m eets the Weekly Abdominal Pain Responder criteria for at least 9 out of the 12 
weeks of the Treatment Period. 
•Weekly Abdominal Symptom Score Responder :AWeekly  Abdo minal Symptom Score
Responder is a patient who has a decrease in the weekly average of the Abdo minal Symptom 
Score of at least 30% com pared wi th the baseline average.  If a patient did not enter 
inform ation into the eDiaryon at l east 4 day s for a parti cular Treatment P eriod week, the 
patient will not be considered a Weekly Abdo minal Symptom Score Responder for that 
week.
•6/12 Week Abdominal Symptom Score Responder: A 6/12 Week Abdo minal Symptom 
Score Responder is a patient who meets the Weekly Abdominal Symptom Score Responder 
criteria for at least 6 out of the 12 weeks of the Treatment Period.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 42of 86•9/12 Week Abdominal Symptom Score Responder: A 9/12 Week Abdo minal Symptom 
Score Responder is a patient who meets the Weekly Abdominal Symptom Score Responder 
criteria for at lea st 9 out of the 12 weeks of the Treatment Period.
•Change from Baseline in 12- week Abdominal Pain: Abdo minal pain is measured daily 
using a n 11-point NRS. The patient’s abdo minal pain score for the Treatment Period is the 
average o f the non -missing daily w orst abdominal pain scores reported by  the pati ent during 
the 12-week Treatment Period.
•Percent Change from Baseline in 12- week Abdominal Pain: Percent change will be 
calculated as the 100 * the Change fro m Baseline in Abdominal Pain divided by  the baseli ne 
Abdo minal Pain score.
•Change from Baseline in 12- week SBM Frequency Rate :A patient’s 12 -week SBM 
frequency  rate will  be the SBM rate (SBMs/week) calculated over the 12 weeks of the 
Treatment Period.
•Change from Baseline in 12- week Stool Consistency: Stool consistency is measured using 
the 7-point BSFS. The patient’s BSFS score for the Treatment Period is the average o f the 
non-missing BSFS scores fro m the SBMs reported by  the pat ient during the 12 -week 
Treatment Period.
•Change from Baseline in 12- week Straining: Straining is measured using a 5 -point ordinal 
scale. The patient’s straining score for the Treatment Period is the average of the non -missing 
straining scores from the SBMs reported by  the patient during the 12 -week Treatment Period.
•Change fr om Baseline in 12 -week Abdominal Discomfort :Abdo minal disco mfort is 
measured daily using a n 11-point NRS. The patient’s abdo minal discomfort score for the 
Treatment Period is the average of the non- missing daily abdo minal disco mfort scores 
reported by  the pati ent during the 12 -week Treatment Period.
•Change from Baseline in 12- week Abdominal Bloating: Abdo minal bloat ing is measured 
daily  using a n 11-point NRS. The patient’s abdo minal bloating score for the Treatment 
Period is the average of the non -missin g daily  abdominal  bloating scores reported by  the 
patient during the 12 -week Treatment Period.
•Change from Baseline in 12- Week Abdominal Symptom Score :The patient’s abdo minal 
symptom  score for the Treatment Period is the average of the non -missing daily abdominal 
symptom scores reported by  the pati ent during the 12 -week Treatment Period.   A patient ’s
daily  abdominal  symptom  score is calculated as the average of the daily abdominal pain, 
abdo minal bloating, and abdo minal disco mfort.   If two or more of the individual daily 
abdo minal symptoms are missing, then the Abdo minal Symptom Score for that day will be 
missing.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 43of 86•Change from Baseline in 12- Week Constipation Severity:   Constipat ion severit y is 
measured weekly using a 5 -point ordinal scale. The patient’s const ipation severit y score for 
the Treatm ent Peri od is the average of the non -missing weekly const ipation severit y scores 
reported by  the pati ent during the 12 -week Treatment Period.
•Change from Baseline in 12- week IBS Symptom Severity :IBS symptom sever ity is 
measured weekly on a 5 -point ordinal scale. The patient’s IBS symptom severit y score for 
the Treatm ent Peri od is the average of the non -missing weekly IBS symptom severit y scores 
reported by  the pati ent during the 12 -week Treatment Period.
•Change fr om Baseline in 12 -Week Percent of Days with Use of Rescue Medicine :The 
percent of day s using per- protocol  rescue medicine or any  other laxat ive, suppository, or 
enema during the Treatment Period will be calculated as 100 * the number of days rescue 
medic ine was used during the Treatment Period divided by  the total  number of days on 
treatm ent.
•Treatment Satisfaction :Treatment satisfaction is measured on a 5 -point ordinal scale. 
Treatment satisfact ion will be analyzed separately at each post -dose visit.
•Adequate Relief :  Assessment of adequate relief during the previous 7 day s is measured on a 
binary  scale (y es/no).  Assessment of adequate relief will be analyzed separately at each post -
dose vi sit.
•6/12 Week Adequate Relief Responder :  A 6/12 Week Adequate Relief Responder i s a 
patient who reports Adequate Relief for at least 6 out of the 12 weeks of the Treatment 
Period.
•9/12 Week Adequate Relief Responder :  A 9/12 Week Adequate Relief Responder is a 
patient who reports Adequate Relief for at least 9out o f the 12 weeks of the Treatment 
Period.
7.9.2.1 Sustained Responders
Select 9/12 Week and 6/12 Week responder parameter will also be assessed for as sustained 
response to determine if the treatment effect is maintained during weeks 9 to 12 of the treatment 
period.  A 9/12 Week Sustained Responders is a patient meet ingthe 9/12 Week Responder 
definit ion, plus are weekly responders for 3 of the last 4 weeks (weeks 9- 12) of the treatment 
period.  A 6/12 Week Sustained Responders is a patient meet ingthe 6/12 Week Res ponder 
definit ion, plus are weekly responders for 2 of the last 4 weeks (weeks 9- 12) of the treatment 
period.  The Sustained Responder definit ion will be applied to the fo llowing response endpo ints:
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 44of 86•APC+1 Responder
•CSBM+1 Responder
•Abdo minal Pain Responder
7.9.2.2 Analys es of Other Efficacy Parameters
All categorical responder parameters (e.g., Weekly CSBM +1 Responder) and CSBM (SBM) 
with 24-hours of first dose, will be analyzed utilizing the same methods defined above for the 
key efficacy  measure 6/12 Week APC + 1 Responder.
All continuous change -from-baseline in 12 -week efficacy  parameters will  be evaluated using an 
ANCOVA model wit h treatment group and geographic region as fixed -effect terms and baseline 
value as a covariate. Least -squares (LS) means for each tr eatment group, LSmean differences 
between each linaclot idedose and pl acebo and their corresponding confidence intervals, and p -
values for the pairwise co mpar isons versus placebo will be presented. 
 
For Treatment Satisfact ion, inferent ial testing will be evaluated emplo ying a MMRM framework 
with week (categori cal), treatm ent, and week -by-treatm ent fixed effects, and patient as the 
rando m effect. The covariance structure will be unstructured. Pairwise co mpar isonsbetween 
each treatment group and placebo will be performed overall and at each visit.  Associated 
LSMeans, LSMeans differences and confidence intervals will be presented.
For Change from Baseline in 12 -Week CSBM, SBM, Stool Consistency (BSFS and 5 point 
ordinal score), Abdo minal Pain, Abdo minal Discomfort, Abdo minal Bloat ing, and the 
Abdo minal Symptom Co mposite Score, sensit ivity analyses will be performed by applying the 
same ANCOVA model to the rank -transform ed data. Change and baseline values will be ranked 
based on the normalizat ion method of Blo m with ties set to the mean.  If the results of the 
sensit ivity analysi s show consistency  with those obtained from  the ori ginal analysis, only  resul ts 
from the original  ANCOVA will be reported.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 45of 86For Change from Baseline in weekly SBM, Stool  Consistency (B SFS and 5 point ordinal score),
Abdo minal Disco mfort, Abdo minal Bloat ing,and the Abdo minal Symptom Composite Score, an 
ANCOVA with treatment and geographic region as fixed effects and baseline as a covariate will 
be fit.  All pairwise comparison sperformed for the 12 -week analyses will be performed for each 
week.
7.10 POSITIVE CONT ROL
The 290 µ g linaclot ide dose is FDA -approved for the treatment of IBS -C(Linzess®) and is 
included in the current trial to evaluate assay sensit ivity and to provi de com parative data for the 
patient popul ation treated wi th 290 µ g linaclotide within the linaclot ide program. Linaclot ide 
290 µ g will be co mpared to placebo utilizing the same method described for pairwise 
comparison described in Sect ion 7.9.
7.11 SAFETY ANALYSIS
The safet y analysis will be performed us ing the Safet y Popul ation. The safety  parameters will 
include AEs, clinical laboratory  and vi tal sign parameters, and physical examinat ion. For each of 
the clinical laboratory  and vi tal sign parameters, the l ast non -missing safet y assessment before 
the first dose of doubl e-blind drug will be used as the baseline for all analyses of that safet y 
param eter. 
Continuous variables will be summarized by number of patients and mean, SD, median, 
minimum, and maximum values. Categorical variables will be summarized by number and 
percentage of patients .
7.11.1 Adverse Events
Adverse events will be coded by  system  organ class and preferred term using the MedDRA
dictionary,versio n 18.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 46of 86An AE that occurs during the Treatment Period will be considered a treatment -emergent advers e 
event (TEAE) if it started after the first dose of double -blind study  drug or was present prior to 
the date of the first dose of double -blind study  drug butincreased in severit y after the fi rst dose 
of doubl e-blind study  drug . If more than 1 AE was repo rted before the first dose of double -blind 
study  drug and coded to the same preferred term, the AE with the greatest severit y will be used 
as the benchmark for comparison wit h the AEs occurring during the Treatment Period. An AE 
that occurs more than on e day after the date of the last dose of double -blind study  drug will not 
be considered as a TEAE.
The number and percentage of patients reporting TEAEs in each treatment group will be 
tabul ated by  system  organ cl ass (SOC) and preferred term and further categ orized by  severi ty
andrelati onship to the study  drug. If a patient has more than 1 AE coded to the same preferred 
term, the pati ent will be counted only once for that preferred term using the highest severit y and 
closest rel ationship to study  drug for th e summarization by severit y and rel ationshipto study  
drug, respectively . 
The incidence of commo n (≥
2% of  patients in any treatment group) TEAEs will be summarized 
by preferred term and treatment group for the Treatment Period. 
A serious adverse event (SAE) that occurred between the date of the first dose of double -blind 
study  drug and 30 d
ays after the date of the last dose of double -blind study  drug , inclusive, will 
be considered an on -therapy  SAE. The number and percentage of pat ients who have on -therapy  
SAEs will be summarized by preferred term and treatment group. In addition, the incid ence o f 
on-therapy  SAEs that l ed to death will be summarized separately  by preferred term  for each 
treatm ent group.
The number and percentage of patients in the Safety Populat ion who have AEs leading to 
prem ature di scontinuati on of  the study  drug will be s ummarized by  preferred term  and treatm ent.
For pati ents experiencing a TEAE coded as diarrhea, the number of days from first dose of study  
drug for the Treatment Period to the onset date of the first occurrence of treatment -emergent 
diarrhea during the Tre atment Period will  be summarized by treatment group using descriptive 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 47of 86statist ics.  In addit ion, the incidence of treatment -emergent diarrhea by time of first onset for the 
Treatment Period will be calculated for each treatment group.
For the Screened Popul ation, listings will be presented for patients who died, patients with SAEs, 
and pat ients with AEs leading to premature discontinuat ion, if any.
7.11.2 Clinical Laboratory Parameters
Descript ive statistics for clinical laboratory values (in SI units) and changes from the baseline 
values at each assessment time po int will be presented by  treatm ent group for the fo llowing 
laboratory  parameters:
Hem atology: Absolute and different ial white blood cell count, ery throcyte count, 
hemoglo bin, hematocrit, platelet count, an d red bl ood cell  indices (m ean 
corpuscular vo lume, m ean corpuscul ar hemoglo bin, and mean corpuscular 
hemoglo bin concentration)
Chemistry : Sodium, magnesium, potassi um, calcium, chl oride, gl ucose, bl ood urea 
nitrogen, creatinine, total protein, alkaline ph osphatase, albumin, total 
bilirubin, aspartate aminotransferase, alanine aminotransferase, bicarbonate, 
phosphate, and cholesterol
Clinical laboratory  test val ues will  be considered potenti ally clinically significant (PCS) if they 
meet ei ther the l ower -limit or hi gher-limit PCS criteria listed in Table 3. The number and 
percentage of patients who have PCS post -baseline clinical laboratory  values will be tabulated by  
treatm ent group for the Treatment Period. The perc entages will be calculated relative to the 
number of patients with available non -PCS baseline values and at least 1 assessment in the 
corresponding post
-baseline period. The numerator will be the total number of pat ients with 
available non -PCS baseline val ues and at l east 1 PCS value in the corresponding post- baseline 
period. A supportive list ing of patients with PCS post -baseline values will be provided, including 
the PID num ber, tri al center, baseline and all post -baseline (including non -PCS) values. A li sting 
of all AEs for patients with post-baseline PCS l aboratory  values will also be provided.
: 19-Oct-2016 15:05
Document Date: 
linaclotide  Ironwood Pharmaceuticals, Inc. 
Statistical Analysis Plan: MCP-103
-204-SAP-01  04 Octob er 2016 
 
Confidential Page 48 of 86 Table 3. Criteria for Potentially Clinic ally Significant Laboratory Results 
Parameter SI Unit Lower Limit Higher Limit 
CHEMISTRY 
Albumin g/L < 0.9 × LLN > 1.1 × ULN 
Alanine aminotransferase U/L — ≥ 3 × ULN 
Alkaline phosphatase U/L — ≥ 3 × ULN 
Aspartate aminotransferase U/L — ≥ 3 × ULN 
Bicarbonate mmol/L < 0.9 × LLN > 1.1 × ULN 
Bilirubin, total  μmol/L — > 1.5 × ULN 
Calcium mmol/L < 0.9 × LLN > 1.1 × ULN 
Chloride mmol/L < 0.9 × LLN > 1.1 × ULN 
Cholesterol, total mmol/L — > 1.6 × ULN 
Creatinine μmol/L — > 1.3 × ULN 
Glucose mmol/L < 0.8 × LLN > 1.4 × ULN 
Magnesium mmol/L < 0.9 × LLN > 1.1 × ULN 
Phosphate mmol/L < 0.9 × LLN > 1.1 × ULN 
Potassium mmol/L < 0.9 × LLN > 1.1 × ULN 
Protein, total  g/L < 0.9 × LLN > 1.1 × ULN 
Sodium mmol/L < 0.9 × LLN > 1.1 × ULN 
Urea nitrogen mmol/L — > 1.2 × ULN 
Uric acid  μmol/L < 0.9 × LLN > 1.1 × ULN 
HEMATOLOGY 
Basophils, absolute cell 
count 109/L — > 3 × ULN 
Eosinophils, absolute cell 
count 109/L — > 3 × ULN 
Hematocrit Ratio < 0.9 × LLN > 1.1 × ULN 
Hemoglobin g/L < 0.9 × LLN > 1.1 × ULN 
Lymphocytes, absolute cell 
count 109/L < 0.8 × LLN > 1.5 × ULN 
Mean corpuscular 
hemoglobin pg — > 3 × ULN 
Mean corpuscular 
hemoglobin concentration g/L — > 3 × ULN 
Mean corpuscular volume fL < 0.9 × LLN > 1.1 × ULN 
Monocytes, absolute cell 109/L — > 3 × ULN 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 49of 86Table 3. Criteria for Potentially Clinically Significant Laboratory Results
Parameter SI Unit Lower Limit Higher Limit
count
Neutrophils, absolute cell 
count109/L < 0.8 × LLN > 1.5 × ULN
Platelet count 109/L <0.5 × LLN >1.5 × ULN
Red blood cell count 1012/L < 0.9 × LLN > 1.1 × ULN
White blood cell count 109/L <0.7 × LLN >1.5 × ULN
LLN =lower limit of normal value provided by the laboratory; SI =Le Système International d’Unités (International 
System of Units) ; ULN =upper limit of normal value provided by the laboratory.
7.11.3 Vital Signs
Descript ive statistics for vital signs (systolic and diastolic blood pressures, pulse rate, respiratory  
rate, tem perature, and weight) and changes fro m baseline values at each vi sit and at the end of 
study  will be presented by  treatm ent group for the Treatment Period.
Vital sign values will be considered PCS if they meet both the observed -value criteria and the 
change -from -baseline criteria listed in Table 4. The number and percentage of patients with PCS 
post-baseline values will be tabulated by treatment group for the Treatment Period. The 
percentages will be calculated relat ive to the number of patients with baseline values and at least 
1 post -baseline assessment for the Treatment Period. The numerator will be the total number of 
patients wi th available baseline values and at least 1 PCS post
-baseline value for the Treatment 
Period. A supportive list ing of patients with PCS post -baseline values will be provided, including 
the PID num ber, tri al center, baseline and all post -baseline (including non -PCS) values.
In addit ion, a list ing of all AEs that occurred in patients who had PCS post -baseline vital sign 
values will be provided.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 50of 86Table 4. Criteria for Potentially Clinically Significant Vital Signs
Parameter FlagCriteriaa
Observed Value Change From Baseline
Sitting systolic blood 
pressure, mm HgHigh ≥ 180 Increase of ≥ 20
Low ≤ 90 Decrease of ≥ 20
Sitting dia stolic blood 
pressure, mm HgHigh ≥ 105 Increase of ≥ 15
Low ≤ 50 Decrease of ≥ 15
Sitting pulse rate, bpmHigh ≥ 120 Increase of ≥ 15
Low ≤ 50 Decrease of ≥ 15
Weight, kgHigh — Increase of ≥ 7%
Low — Decrease of ≥ 7%
a.A post -baseline value is con sidered potentially clinically significant if it meets both the observed -value and the 
change -from -baseline criteria.
bpm =beats per minute.
7.11.4 Other Safety Parameters
7.11.4.1 Physical Examination
Any physical examinat ion abnormalit y that the investigator consider s to be potenti ally clinically 
significant and changed from the baseline will be reported as an AE. No separate analysis for 
Physical Exam inations is pl anned.
7.12 HEALTH O
UTCOMES A NALYSIS
Health outcom e analyses will be performed on the ITT populat ion.  
7.12.1 Short Form -12 Health Survey Version 2 
The higher -order norm -based scores, Physical Component Summary  (PCS -12) and Mental 
Com ponent Summary (MCS -12), will be computed at Randomizat ion, Week 4, Week 8, and 
EOT. Descript ive statist ics (n, m ean, SD, m edian, minim um, and m aximum ) will  be presented 
for the abso lute and change -from-baseline by visit . Treatm ent differences for the change from 
baseline at each post -dose visit will be analyzed using an ANCOVA with treatment and 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 51of 86geographi c regi on as fixed effects and bas eline summary  score as a covariate .(See Section 
9.12.1 for scal e scoring)
7.12.2 EuroQol -5 Dimension ( EQ-5D-3L)
Patient responses to the descriptive system (i.e., health state) will be converted to the 
corresponding u
tility score and the descript ive statistics (n, mean, SD, median, minimum and 
maximum) will be presented for utilit y score by  treatm ent group.  The same statist ics will be 
calculated for the analog scale reflect ing the patient’s preference for their healt hstate.  Results 
will be presented at baseline and at each post- baseline week using both observed case ( OC)and 
last observat ion carri ed forward ( LOCF )approaches to missing post -baseline data. (See Section 
9.12.2 for scal e scoring)
7.12.3 Short Form McGill Pain Questionnaire -2 (SF -MPQ -2) 
At each assessment of the SF-MPQ -2, total pain score and the 4 subscales (Continuous pain, 
Intermittent pain, Neuropathic pain, and Affective pain )will be calculated. Descript ive statistics 
and the change from baseline will be presented for each score. Treatment differences wit h 
respect to change fro m baseline will be assessed using an ANCOVA with treatment and 
geographi c regi on as fixed effects and baseline value as a covariate. (See Section 9.12.3 for scale 
scoring)
7.12.4 Irritable Bowel Syndrome -
Symptom Severity Scale ( IBS-SSS)
At each assessment of the IBS- SSS, the IBS- SSS Total score will be calculated. Descript ive 
statist ics will be presen ted for the IBS- SSS Total score and each severit y score .  (See Section 
9.12.4 for scal e scoring)
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 52of 868. CHANGES FROM ANALYSE S PLANNED IN THE 
PROTOCOL
a.For the key  efficacy parameters Weekly Change from Baseline in Abdo minal Pain and 
Weekly Change from Baseline in CSBM Frequency , the protocol  states:
Additional exploratory comparisons between the linaclotide doses (DR1, DR2) and 
linaclotide IR,  
 
 All other comparisons between linaclot ide dose (DR1, DR2, and IR) 
will be performed descript ively.
b.For 6/12 Week APC+1 Responder rate , the protocol st ates:
If the overall CMH statistic reaches statistical signifi cance (α = 0.05), the tested formulation 
will be considered efficacious and the nature of the dose response w ill be explored among 
the individual linaclotide DR doses w ithin the formulation.  
TheSAP clarifies statistical inference co mpare sPlacebo to each DR1 and DR2 doses only , 
regardl ess of the overall trend significance.   All other treatment comparisons will be 
descript ive in nature.
c.For each 6/12 Week and 9/12 Week responder endpoint defined in the protocol, a 
corresponding “Sustained Responder” was added.  Each new ‘Sustained Responder’ 
param eter will be presented and analyzed as described in Sect ions 7.9.1.1 and 7.9.1.2
d.For the analyses of the 12 -week Change fro m baseline, the protocol state s:
 
 
 All other comparisons between linaclot ide dose (DR1, DR2, and IR) 
will be performed descript ively.
e.For all responders in the “Other Efficacy Endpo int” section, the protocol states:
All categorical responder parameters (e.g., Weekly CSBM +1 Responder) w ill be analyzed 
utilizing the same methods defined above for the key efficacy measure 6/12 Week APC +1 
Responder.
The SAP clarifies statistical inference co mpares Placebo to each DR1 and DR2 doses only.  
All other treatment comparison s will be descript ive in nature.
f.For pati ents experiencing a TEAE coded as diarrhea, analyses of the number of days from 
first dose of study  drug for the Treatment Period to the onset date of the first occurrence of 
treatm ent-emergent diarrhea during the T reatment Period listed in the SAP were not 
ident ified in the protocol.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 53of 86g.The endpo ints and analyses of 6/12 and 9/12 Week Adequate Relief were not specified in the 
protocol .
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 54of 869. DATA HANDLING CONVEN TIONS
9.1 VISIT TIME WINDOWS FOR SAFETY ANALYSIS
Table 5below presents the visits assigned for the safet y analysis corresponding to the range of 
trial days (window) during which an actual visit may  have occurred.
Table 5. Visit Time Windows for Safety Analys is
Derived Visit Scheduled Test / Visit DayaWindow
Baseline Day 1 Days ≤ 1
Day 29 Visit Day 29 Days [2, 43]
Day 57 Visit Day 57 Days [44, 71]
Day 85 Visit Day 85 Days [72, 99]
End of TrialbFinal or termination visit
a.Relative to the date o f randomi zation ; Day 1 = the day of randomization .
b.“End of Trial” will be presented in analysis tables for safety parameters, including clinical laboratory and vital 
signs.
Test/Vi sit Day  will be calculated as fo llows:test/visit date –date of rando mizat ion.
9.2 VISIT TIME WINDOWS FOR EFFICACY ANALYSIS
Table 6presents the analysis weeks assigned for the efficacy analysis of the patient diary data 
related to BM characteristics. These analysis weeks will be used in the calculat ions f or all week -
based param eters (e.g., SBM weekly frequency  rate, BSFS weekly  scores).
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 55of 86Table 6. Analysis Time Windows for Efficacy Analysis
Period Analysis Week BeginsaEndsa
Pretreatment 
(Baselineb)Week –2 Day –14 Day –8
Week –1 Day –7Day 1 (time of 
randomization )
TreatmentWeek 1 Day 1 (time of randomization ) Day 7
Week 2 Day 8 Day 14
Week 3 Day 15 Day 21
Week 4 Day 22 Day 28 
Week 5 Day 29 Day 35
Week 6 Day 36 Day 42
Week 7 Day 43 Day 49 
Week 8 Day 50 Day 56
Week 9 Day 57 Day 63
Week 10 Day 64 Day 70 
Week 11 Day 71 Day 77 
Week 12 Day 78last dose dayc(usually 
Day 85)
Note: There is no Day 0 or Week 0. For eDiary assessments in which a patient is asked to report if an event occurre d 
“yesterday” or “today” (e.g., a bowel movement or rescue medication use), these windows pertain to when the event 
occurred, not to when the event is reported. For example, if a patient reports in eDiary on Day  78 a bowel movement 
occurring “yesterday,” t hat bowel movement (and subsequent stool consistency and straining scores) would be 
included in Analysis Week 11, not Analysis Week 12. 
a.Relative to the date o f randomization ; Day 1 = the day of randomization . For the calculation of rates (e .g., stool 
frequency  rates) in which the duration of a week or the overall period is calculated to the nearest hour, a day 
begins and ends at midnight. 
b.Baseline values for efficacy paramet ers will be derived from the daily  eDiary and eCRF data collected in the 
Pretreatm ent Period, specifically the period from 14 days before randomization up to the time of randomization.
c.For patients who fail to provide the date of last dose at the last visit, the last eDiary date will be used to impute 
the last dose date.
For the Treat ment Period, diary day is calculated as di ary date –date of rando mizat ion + 1 . For 
the Pretreatment Period , diary day is calculated as di ary date -date of rando mizat ion. However, 
the day  of rando mizat ion is always trial Day 1. Patients will co mplete thei r diary entri es once a 
day, with the excepti on of  Day  1 of entry  into the Treatment Period during which 2 diary  data 
sets will be co llected. On Day 1, daily quest ions will be entered before and after the 
rando mizat ion, whereas weekly questions will be ente red before but not after randomizat ion.
If a patient withdraws during the Treatm ent Peri od, the pati ent’s Treatm ent Peri odshall end on
the day  of the l ast dose. The affected Treatment Period week shall be shortened to the end of the 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 56of 86withdrawn pati ent’s Treatm ent Peri od,and all subsequent Treatment Period weeks will be 
missing for that patient.
9.3 POOLING OF TRIAL CENTERS
Because of the potenti al of many trial  centers to have a small  number of patients, the centers will 
be pool ed by the fo llowing 5 geographi cregions (as listed in Table 7): Northeast, Southeast, 
Midwest, Southwest, and West. All analyses u sing tri al center will use this 5 -category  center 
variable.
Table 7. Definition of Geograph ic Region s
Northeast Southeast Midwest Southwest West
CT AL IA AZ CA
DE AR IL NM CO
MA FL IN OK ID
MD GA KS TX MT
ME KY MI NV
NH LA MN OR
NJ MS MO UT
NY NC ND WA
PA SC NE WY
RI TN OH
VT VA SD
WV WI
9.4 DERIVED EFFICACY VARIABLES
9.4.1 Patient Recall for eDiary Data
Bowel Habits
The eDiary is designed to allow pat ients to enter Daily  Bowel  Habi ts through a spontaneous 
report or the evening report.  
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 57of 86The spontaneous report allows the patient to report BM s, occurring between evening reports, a t 
any time .  If the previ ous evening report was not completed, then the patient can report BM 
inform ationoccurring between 7:00 PM of the previous night and the current spontaneous report.
The evening report allows the patient to report BM informat ion bet ween the time o f the previous 
evening report and the current evening report (~24-hour recall) .  If the previ ous evening report 
was not com pleted, then the patient can report BM informat ion within the evening report 
occurring between 7:00 PM of the previous night and the current evening report.
These BM informat ion reporting rules were put into place to reduce recall bias.
Rescue Medicine (RM)
The spontaneous report allows the patient to report RM informat ion, occurring between evening 
reports, at any  time. If the previous evening report was not completed, then the patient can 
report RM informat ion between 7:00 PM of the previous night and the current spontaneous 
report.
The evening report allows the patient to report RM informat ion between the time o f the previous 
evening report and the current evening report (~24-hour recall) .  If the previous evening report 
was not com pleted, then the patient can report RM informat ion within the evening report 
occurring between 7:00 PM of the previous night and the current evening report.
These RM informat ion reporting rules were put into place to reduce recall bias.
Abdominal Symptom Severity
During the Evening Diary  Report, the eDiarywill capture separately the rating of abdominal
pain, bloat ing,and disco mfort experi enced by  the pati ent during the past 24 hours.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 58of 869.4.2 Handling of Missing eDiary Data 
In the eDiary, for each BM and rescue medicine use reported, the patient will be asked whether 
the BM or rescue medicine use occurred “today ” or “yesterday .” The fo llowing conven tions will  
be followed in the event of missing data:
Gaps in the eDiary Data
If a patient does not complete either a spontaneous or evening report every day, there will be 
gaps in the data. 
There will be no adjustments for these gaps in the eDiarydata fo r the efficacy data analyses 
using an OCapproach. Effect ively, this means that analyses will assume that no rescue medicine
use orBMs occur redduring these gaps.
Missing “Today” or “Yesterday” Information for Rescue Medicine
When a pat ient uses rescue medicine and the exact date of use is known, there will be a 2-day 
window during which any BMs will not be assessed as SBMs: (1) the day  when the rescue 
medic inewas administered and (2) the day  after. If ,in the daily  diary ,a pati ent has reported
taking a rescue medicine but the corresponding date is missing, the rescue medicine use must 
have occurred either on the day  of the diary entry  or on the day  before the diary entry . The rescue 
medicine window in this missing- date scenario will be 3 days, covering t he day  before the 
eDiaryreport, the day  of the eDiaryreport ,and the day after the eDiaryreport . This window will 
be used to determine if a BM shoul d be considered an SBM.
For the analysis o f rescue medicine s, the missing date will be imputed as the dat e in which the 
rescue medicine was reported.
Missing “Today” or “Yesterday” Information for Bowel Movements
If a patient reports having had a BM but does not provide the exact date, the BM must have 
occurred either on the day  of the report or on the day  before the report . For determining whether 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 59of 86a BM i s an SBM, thi s 2-day window will  be used in conjunct ion with the rescue medicine
window. If there is any overlap between the BM window and thepatient’s rescue medicine
window, the BM will not be considered an SBM.
Many  analyses requi re specific dates for each BM. If a BM date is missing, it will be imputed as 
the date /time stamp o f the eDiaryreport in which the BM was reported. However, the following 
exception applies to this imputati on rul e:
When the first d ay of the BM window isthe last day  of a rescue medicine window and the 
second day  of the BM window is not also a day  of arescue medicine window, the missing BM 
date will be imputed as the first day  of the BM window (i .e., the day  before the eDiary report in 
which the BM was re corded ).This rule of excepti on is designed to minimize the risk of 
mischaracterizing a non -spontaneous BM as an SBM.
Missing Stool Consistency Questions
No im putati on will be perform ed for amissing BSFS score or the stool  consisten cy 5 point 
ordinal measure.
Missing Completeness of Evacuation Response 
If the completeness of e vacuat ion response (Quest ion #12 ) is missing, an SBM will not be 
considered complete.
Missing Daily Abdominal Symptoms
No im putati on will be perform ed for miss ing daily symptoms (Abdo minal Pain, Abdominal 
Discomf ort, Abdominal Blo ating) .
: 19-Oct-2016 15:05
Document Date: 
 
Confidential Page 60 of 86  9.4.3 Weekly Stool Frequency Rates  
The components for calculating a patient’s stoo l frequency rates (BM, SBM, and CSBM weekly 
rates) for a given analysis week are as follows: 
• The number of BMs that occurred  during that analysis week 
• The number of those BMs that were SBMs 
• The number of those SBMs that were CSBMs 
• The length of time of the analysis week 
• The determination of the length of time of an analysis week is provided in Section 9.4.3.1. 
 
9.4.3.1 Length of an Analysis Week 
With respect to a patient’s scheduled analysis weeks, the term duration is used. In regard to the 
duration of a week, it is expected that 1 or more of  a patient’s “weeks” may not be exactly 7×24 
hours in duration (e.g., a patient may withdraw or discontinue early from the trial). Deviations 
from the 7×24–hour norm are structur al in nature; and, as such, the calculations of the weekly 
rates of SBMs or CSBMs will incorporate the actual duration of the week. 
Following an observed-cases approach, no adjustment to the duration of a week will be made for 
missing eDiary data absent because of missed reports. 
9.4.3.2 Weekly Stool Frequency Rate Calculations 
The weekly frequency rate for SBMs (CSBMs) will be based on the number of SBMs (CSBMs) 
occurring during that week, adju sting for differences in the duration of the week versus the 
7×24–hour norm. A description of the corr esponding formula is provided below. linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 61of 86Weekly stool frequency  rates f or each analysis week will be calculated as follow s:
Weekly Frequency Rate (Analysis Week i)= (7 × 24) × Ci/Di
Where :
iis an indicator ofanalysis week number (e.g., i= –2, –1, 1, …, 12),
C
iis the number of events (SBMs or CSBMs) reported during analysis week i
,and
D
iis the duration (in hours) of analysis week i,from beginning to end ( Table 6).
9.4.3.3 Overall Weekly Stool Frequency Rate Calculations for Each Analysis 
Period
For each of the 2analysis periods (Pretreatment and Treatment), the overall weekly stool 
frequency  rates will  be calculated in a m anner similar to that for an individual week. The 
corresponding formulas are provided below.
Overall weekly  stool  frequency  rates f or each analysis period will be calculated as fo llows:
Weekly Frequency Rate (Analysis Period j)= (7 × 24) × Cj/Dj
Where:
jis an indicator of analysis period number (e.g., j= 1 [pretreatment ]
, 2 [treatm ent]),
C
jis the number of events (SBMs or CSBMs) reported during analysis period j,and
D
jis the duration (in hours) of analysis peri od j, from beginning to end ( Table 6).
9.4.4 Other Weekly Scores Derivation 
For Abdo minal Pain, Bloating, and Disco mfort, the pati ent’s weekly  average will be the average 
of the non -missing daily scores reported by the p atient during each week.
For stool consistency quest ions, the pati ent’s weekly  score will be the average of the non
-
missing daily scores from  the SBMs reported by  the pati ent during each week. 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 62of 86For straining, the patient’s weekly straining score will be th e average of the non-missing daily  
straining scores from the SBMs reported by  the patient during each week. 
For the abdo minal symptom co mposite score, first the daily average o f Abdo minal Pain, 
Abdo minal Bloating and Abdominal Discomfort will be calculate d.  If  more than 1 of the 
symptom  score sis missing on a day , that daily  abdominal  symptom  com posite score will  be 
missing.  Weekly  scores will be based on the average of the non -missing abdo minal symptom 
composite score s
.
9.5 REPEATED OR UNSCHEDU LED ASSESSMEN TS OF SAFETY 
PARAMETERS
If a patient has repeated assessments prior to the start of double -blind study  drug, then the results 
from the final non -missing assessment made prior to the start of the double -blind study  drug will 
be used as baseline. If end-of-study assessments are repeated or if unscheduled visit s occur, the 
last non -missing post baseline assessment will be used as the end -of-study  assessment for 
generat ing summary statist ics. However, all post -baseline assessments will be used for PCS 
value det ermination as described above and all  assessments will be presented in the data list ings.
9.6 MISSING DATE OF THE LAST DOSE OF STUDY DRUG
When the date of the last dose of double -blind study drug is missing for a patient in the Safet y 
Popul ation, all efforts s hould be made to obtain the date from the Invest igator. If after all efforts 
are made it is st ill missing, the last eDiary entry will be used as the l ast dose date. 
9.7 MISSING SEVERITY ASS ESSMENT FOR ADVERSE EVENTS
If severit y is missing for an AE started pr ior to the first double blind study  drug , allefforts 
shoul d be made to obtain the severit yfrom the investigator. If it is still missing after all efforts, 
then a severit y of “Mild” will be assigned. If the severit y is missing for an AE started on or afte r 
the date of the first dose of double -blind study  drug, then a severit y of “Severe” will be assigned. 
The imputed values for the missing severit y assessment will be used for the incidence summary, 
while the actual missing values will be presented in data listings.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 63of 869.8 MISSING RELATIONSHIP TO STUDY DRUG FOR ADVERSE 
EVENTS
If the relat ionship to study  drug is missing for an AE started on or after the date of the first dose 
of doubl e-blind study  drug, all  efforts shoul d be made to obtain the date from the investi gator. If 
it is still missing after all efforts ,a causalit y of “Related” will be assigned in the corresponding 
analysis derived data set . The imputed values for the missing relati onship to doubl e-blind study  
drug will be used only for incidence summary , while the actual missing values will be presented 
in data list ings.
9.9 MISSING DATE INFORMATION FOR ADVERSE EVE NTS
The fo llowing imputati on rul es apply  to cases in which the start date is incomplete ( i.e.,partial 
missing) for adverse events
.
a.If AEs occurred d uring the Screening or Pretreatment Period (i.e., the Screening or 
Pretreatment Period is checked on the AE eCRF)
Missing day and month
•If the year is the same as the y ear of  the date of informed consent, then the day  and m onth of 
the date of informed con sent will be assigned to the missing fields.
•If the year is prior to the year of the date of informed consent, then December 31 will be 
assigned to the missing fields.
•If the year is after the year of the date of informed consent, then January 1 will be as signed to 
the missing fields.
Missing month only
•The day  will be treated as missing and both month and day  will be repl aced according to the 
above procedure.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 64of 86Missing day only 
•If the month and y ear are the same as the month and year of the date of inform ed consent, 
then the date of informed consent will be assigned to the missing day .
•If eit her the y ear is before the y ear of the date of informed consent or if both y ears are the 
same but the month is before the month of the date of informed consent, then t he last day  of 
the month will  be assigned to the missing day .
•If eit her the y ear is after the y ear of the date of informed consent or if both y ears are the same 
but the m onth is after the m onth of the date of info rmed consent, then the first day  of the 
month will be assigned to the missing day.
If the stop date is co mplete and it is before the date of rando mization and the imputed start date 
as above is after the stop date, the start date will be imputed by the stop date. If the stop date is 
complete and i t is on or after the date of randomization and the imputed start date as above is 
after the stop date, the start date will be imputed by  the date immediately  before the date of 
rando mizat ion.
If the start date is co mpletely missing, then the date of inform ed consent will be used to impute 
the start date.
b.If AEs occurred during the Treatment Period (i.e., the Treatment Period is checked on 
the AE eCRF)
Missing day and month
•If the year is the same as the y ear of  the date of the first dose of double -blind stu dy drug, then 
the day  and m onth of the date of the first dose of double -blind study  drug will  be assigned to 
the missing fields.
•If the year is prior to the year of the date of the first dose of double -blind study  drug, then 
December 31 will be assigned to the missing fields.
•If the year is after the year of the date of the first dose of double -blind study  drug, then 
January  1 will be assi gned to the missing fields.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 65of 86Missing month only
•The day  will be treated as missing and both month and day  will be repl aced according to the 
above procedure.
Missing day only
•If the month and y ear are the same as the month and year of the date of the first dose of 
doubl e-blind study  drug, then the date of the first dose of double- blind study  drug will be 
assigned to the miss ing day .
•If eit her the y ear is before the y ear of the date of the first dose of double- blind study  drug or 
if both years are the same but the month is before the mo nth of the date of the first dose of 
doubl e-blind study  drug, then the last day  of the month will be assigned to the missing day.
•If eit her the y ear is after the y ear of the date of the first dose of double -blind study  drug or if 
both years are the same but the month is after the mo nth of the date of the first dose of 
doubl e-blind study  drug, the n the first day  of the month will be assigned to the missing day .
•If the stop date is co mplete and the imputed start date as above is after the stop date, the start 
date will be imputed by the stop date.
•If the start date is co mpletely missing and the stop date i s complete, then the following 
algorithm is used to impute the start date:
•If the stop date is after the date of the first dose of double -blind study  drug, the date of the 
first dose of doubl e-blind study  drug will be assigned to the missing start dat e.
•If the stop date is before the date of the first dose of double -blind study  drug, the stop date 
will be assigned to the missing start date. 
9.10 MISSING DATE INFORMATION FOR PRIOR OR CO NCOMITANT 
MEDICATIONS
For pri or or concomitant medications, inco mplete (i.e.,partial lymissing) start date and/or stop 
date will be imputed. When the start date and the stop date are both inco mplete for a patient, 
impute the start date first.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 66of 869.10.1 Incomplete Start Date
The fo llowing rul es will  be applied to impute the missing n umerical  fields. If the stop date is 
complete and the imputed start date is after the stop date, then the start date will be imputed 
using the stop date.
Missing day and month
•If the year of the inco mplete start date is the same as the year of the date of the first dose of 
doubl e-blind study  drug, then the day  and m onth of the date of the first dose will be assigned 
to the missing fields.
•If the year of the inco mplete start date is prior to the y ear of the date of the first dose of 
doubl e-blind study  drug, then December 31 will be assigned to the missing fields.
Missing month only
•The day  will be treated as missing and both month and day  will be repl aced according to the 
above procedure.
Missing day only
•If the month and y ear of  the incomplete start date a re the same as the month and year of the 
date of the first dose of double -blind study  drug, then the day  of the date of the first dose will 
be assigned to the missing day .
•If eit her the y ear is before the y ear of the date of the first dose of double- blind study  drug or 
if both years are the same but the month is before the mo nth of the date of the first dose of 
doubl e-blind study  drug, then the last day  of the month will be assigned to the missing day .
•If eit her the y ear is after the y ear of the date of the first dose of doubl e-blind study  drug or if 
both years are the same but the month is after the mo nth of the date of the first dose of 
doubl e-blind study  drug, then the first day  of the month will be assigned to the missing day .
9.10.2 Incomplete Stop Date
The f ollowing rul es will  be applied to impute the missing numerical fields. If the date of the last 
dose of double -blind study  drug is missing, replace it with the last diary call date. If the imputed 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 67of 86stop date i s before the start date (imputed or non -imputed s tart date), then the imputed stop date 
will be equal to the start date.
Missing day and month
•If the year of the inco mplete stop date is prior to the y ear of the date of the last dose of 
doubl e-blind study  drug, then December 31 will be as signed to the mis sing fields.
Missing month only
•The day  will be treated as missing and both month and day  will be repl aced according to the 
above procedure.
Missing day only
•If eit her the y ear is before the y ear of the date of the last dose of double- blind study  drug or if 
both years are the same but the month is before the month of the date of the last dose of 
doubl e-blind study  drug, then the last day  of the month will be assigned to the missing day .
9.11 CHARACTER VALUES OF CLINICAL LABORATORY PARAMETERS
If the reported v alue of  a clinical laboratory  parameter cannot be used in a statist ical summary  
table due, for example, to it being a character string rather than a numerical t ype, a coded value 
needs to be appropriately determined and used in the statist ical analyses. Ho wever, the actual 
values as reported in the database will be presented in data list ings.
Table 8shows examples of how some possible laboratory  resul ts shoul d be coded for the 
analysis.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 68of 86Table 8. Examples of Coding Special Character Values for Clinical Laboratory 
Parameters
Laboratory Test,
SI UnitPossible Laboratory Results Coded Value for Analysis
CHEMISTRY
ALT, U/L < 5 0
AST, U/L < 5 0
Bilirubin, total, μmol/L < 2 0
ALT =alanine ami notransferase; AST =aspartate aminotransferase; SI =Le Système International d’Unités
(International System of Units).
9.12 HEALTH OUTCOME PARAM ETERS
9.12.1 Short Form 12 Health Survey Version 2
The SF -12 is a m ultipurpose, short -form health survey consist ing o f 12 questions designed for 
use in clinical pract ice and research, healt h policy evaluat ions, and general populat ion surveys. 
The SF -
12, Versi on 2 .0,contains 12items that, when scored, yield an 8 -scale profile o f 
funct ional health and well -being , as well as physic al and m ental  summary  measures. 
The 8 scales (also known as domains) are as fo llows: Physical Functioning (PF), Role Physical 
(RP), B odily  Pain (BP), General Healt h (GH), Vitalit y (VT), Soci al Functi oning (SF), Role 
Emotional (RE), and Mental H ealth (MH) .A norm -based score will be computed for each of the 
8 sca les using standard scoring rules . These rul es generate a standardized score (with a mean of 
50 and a nSDof 10 in the general U.S. Population) for each of the scales such that higher scores 
represent better health condit ion. 
In addit ion, scores fro m these 8scales will be aggregated in 2distinct, higher -order summary  
norm -based scores: Physical Co mponent Summary (PCS -12) and Mental Co mponent Summary 
(MCS -12) scores. These 2 summary  scores wi ll also be standardized to have a mean o f 50 and a n
SDof 10 in the general US Populat ion. 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 69of 86The steps involved in scoring SF- 12 can be found at Ware et al ( 1995) ( 1); they are briefly 
described as fo llows:
Item Recoding
Reverse score items 1, 5, 6a, and 6b so that, for all scales,
higher scores indicate better health 
condi tion. The scores 1, 2, 3, 4, and 5 of items 5, 6a, and 6b will be reversed to 5, 4, 3, 2, and 1. 
For i tem 1, the scores 1, 2, 3, 4, and 5 will be reversed to 5, 4.4, 3.4, 2.0, and 1.0.
Aggregate and Transform Scale Scores
Atransform ed scale score for each scale will be computed by  subtracting the l owest possible 
derived score fro mtheactual derived score, dividing the difference by the corresponding 
possible derived score range, and mult iplying the ratio by  100. Table 9summarizes the process.
Table 9. Summary of Formulas for Scoring and Transforming Scales
ScaleSum Final Item  
Values (After 
Recoding)Lowest and Highest 
Possible Derived 
ScoresPossible Derived 
Score Range
Physical Functioning 
(PF)2a + 2b 2, 6 4
Role-Physical (RP) 3a + 3b 2, 10 8
Bodily Pain (BP) 5 1, 5 4
General Health (GH) 1 1, 5 4
Vitality (VT) 6b 1, 5 4
Socia l Functioning 
(SF)7 1, 5 4
Role-Emotio nal (RE) 4a + 4b 2, 10 8
Mental Health (MH) 6a + 6c 2, 10 8
Compute Standardized Values (z -Scores) for the Short Form -12 Health Survey, Version 
2.0,Scales
A z-score for each scale is co mputed by subtracting the 1998 general US population mean for 
each S F-12 scale and dividing the difference by  the corresponding scale SDfrom the 1998 
general US populat ion (Table 10).
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 70of 86Table 10. 1998 General US Population Means and Standard Deviations U sed 
to Derive S hort Form-
12Health Survey, Version 2.0, z -Scores —
Acute Form
SF-12 Scale MeanaSDa
Physical Functioning (PF) 80.64733 29.71224
Role-Physical (RP) 80.61635 27.84366
Bodily Pain (BP) 83.42495 24.34172
General Health (GH) 71.96134 23.53406
Vitality (VT) 55.11847 25.63085
Socia l Functioning (SF) 84.58234 25.21668
Role-Emotional (RE) 86.79996 22.64927
Mental Health (MH) 71.38235 20.54864
a.The means and SDs for each scale of the Short Form -12 Health Survey, Version 2.0, are based on the 
0-100 s coring.
Compute Aggregate Summary Scores
An aggregate physical and mental summary  score will be co mputed by multiplying the z -score of 
each SF -12 scale by its respect ive factor score coefficient ( Table 11) and sum ming the 8 
products for each summary  score.
Table 11. 1990 Fac t or Score Coefficients Used to Derive Physical Component 
Summary and Mental Component Summary Scale Score s—
Standard and Acute Forms
SF-12 ScaleStandard andAcute Form  Factor Score 
Coefficients
PCS MCS
Physical Functioning (PF) 0.42402 -0.22999
Role-Physical (RP) 0.35119 -0.12329
Bodily Pain (BP) 0.31754 -0.09731
General Health (GH) 0.24954 -0.01571
Vitality (VT) 0.02877 0.23534
Socia l Functioning (SF) –0.00753 0. 26876
Role-Emotional (RE) –0.19206 0.43407
Mental Health (MH) –0.22069 0.48581
MCS = Mental Component Summary; PCS = Physical Component Summary ; SF-12= Short Form -12 
Health Survey .
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 71of 86Compute Norm- Based Summary Scores
This step invo lves transforming the aggregate physical and mental summary scores to the norm-
based (50, 10) scoring (mean = 50 and SD = 10 in the general 1998 US populat ion) by 
multiplying the respect ive aggregate summary score by 10 and adding 50. See Ware et al (1) for 
details o f the stand
ard scoring rules.
If any item is missing in SF- 12, then the PCS -12 and MCS -12 scores will not be calculated and 
will be set to missing.
9.12.2 EuroQol -5 dimension ( EQ-5D-3L)
The 5 -item responses of the EQ -5D-3L define a health state that can be converted into a single 
summary utilit y index that assi gns weights (ie, value) to each level. Different weights are 
available. For this study , the US TTO (time trade -off) weights will be used ( 3).
The EQ -5D-3L index is computed accordi ng to the fo llowing equat ion as: 
EQindex= 1 -{0.146016 ×m1+ 0.557685 ×m2+ 0.1753425 ×s1+ 0.4711896 ×s2+ 
0.1397295 ×u1+ 0.3742594 ×u2+ 0.1728907 ×p1+ 0.5371011 ×p2+ 0.156223 ×a1+ 
0.4501876 ×a2+ -0.1395949 ×d1+ 0.0106868 ×* i22+ -0.1215579 ×i3+ -0.0147963 ×i32}
where the variables m1, s1, u1, p1, a1, m 2, s2, u2, p2, a2 , i2, i22, i3, i32and d 1are given in Table 12.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 72of 86Table 12. E uroQol Quality - of-Life Questionnaire Utility Index
EuroQoL Level 2 Level 3
Mobilitym1= 1 if Level 2 
selected
0 otherwisem2= 1 if Level 3 
selected
0 otherwisem0= 1 if m 1= 0 & 
m2= 0
0 otherwise
Self-cares1= 1 if Level 2 
selected
0 otherwises2= 1 if Level 3 
selected
0 otherwises0= 1 if s 1= 0 & s 2= 0
0 otherwise
Usual activityu1= 1 if Level 2 
selected
0 otherwiseu2= 1 if Level 3 
selected
0 otherwiseu0= 1 if u 1= 0 & u 2= 
0
0 otherwise
Pain/discomfortp1= 1 if Level 2 
selected
0 otherwisep2= 1 if Level 3 
selected
0 otherwisep0= 1 if p 1= 0 & p 2= 
0
0 otherwise
Anxiety/depressiona1= 1 if Level 2 
selected
0 otherwisea2= 1 if Level 3 
selected
0 otherwisea0= 1 if a 1= 0 & a 2= 
0
0 otherwise
Interaction termsi2= max {0, (m 1+ s 1+ u 1+ p 1+a1) – 1}
i22= i2× i2
i3= max {0, (m 2+ s 2+ u 2+ p 2+ a 2) – 1}
i32= i3× i3
d1= max {0, 4 –(m0+ s 0+ u 0+ p 0+ a 0)}
If any dimensio n is missing in the EQ -5D-3L , the EQ -5D-3L index will not be calculated and 
will be set to missing.
9.12.3 Short Form McGill Pain Questionnaire -2 (SF -MPQ -2)
The SF -MPQ -2 is composed of 22 items invest igating 4 dimensio ns.
Dimension of Pain
(Subscales)Number of item s Cluster of items Direction of Score
Continuous 6 1, 5-6, 8-10 Lower score = Lower 
pain Inter mittent 6 2-4, 11, 16, 18
Neur opathic 6 7, 17, 19-22
Affective D escriptor 4 12-15
: 19-Oct-2016 15:05
Document Date: 
 
Confidential Page 73 of 86 Subscale score: For each of the scales, scores are calculated by taking the mean of the item 
ratings included in the scale. 
Total score: mean of all SF-MPQ-2 item ratings Interpretation and Analysis of missing data: - No  correction is necessary for missing data if the 
subject has omitted a few items. Mean scores sh ould be calculated on the available items. 
9.12.4 Irritable Bowel Syndrome-Symptom Severity Scale (IBS-SSS) 
The IBS-SSS has 2 severity questions each with a 0-10 point rating scale where a higher score 
represents greater severity or poorer quality of life (see Appendix V ), one frequency of pain (0-
10) over the last 10 days ques tion, one dissatisfaction score w ith a 0-10 point rating where a 
higher score represents greater dissatisfaction, an d one indication of how much pain, discomfort 
or altered bowel interfere with general life score with a 0-10 scale where a higher score 
representing greater interferen ce.  The IBS-SSS total score will be the average of the 5 non-
missing scores described above. linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 74of 8610. REFERENCES
1.Ware John E.Jr., Kosinski M. A 12- Item Short -Form Healt h Survey: Construction of Scales 
and Preliminary  Tests of Reliabilit y and Validi ty. Med Care 1996;34:220 -33.
2.EuroQol --a new facilit y for the measurement of health -related qualit y of life. The EuroQol  
Group. Health Policy 1990 Dec;16(3):199-208.
3.Shaw JW, Johnson JA, Coons SJ. U.S. valuat ion of the EQ -5D healt h states: development 
and testing of the D1 valuat ion model. Med Care 2005;43:203 -20.
4.Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce -Sandner S, et al. 
Development and init ial validat ion of an expanded and revised versio n of the Short -form 
McGill Pain Quest ionnaire (SF -MPQ -2). Pain 2009 Jul;144(1 -2):35 -42.
5.Francis C, Morris J, Wh orwell  P:The i rritable bowel  severi ty scoring system : a simple 
method of monitoring irritable bowel syndro me and its progress.  Aliment Pharmaco l 
Ther 1997, 11:395 -402.
6.Ratitch, B., O'Kelly, M. and Tosiello, R. (2013), Missing data in clinical trials: fro m clinical 
assumpt ions to stati stical analysis using pattern mixture models. Pharmaceut. Statist., 
12: 337–347. doi: 10.1002/pst.1549
7.Rubin DB (1987) Mult iple Im putati on for Nonresponse in Surveys. John Wiley  & Sons Ltd., 
New York.
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 75of 86APPENDIX I. BRISTOL STOOL FORM S CALE
Type 1 -Separate hard lumps like nuts (difficult to pass)
Type 2 -Like a sausage but lumpy
Type 3 -Like a sausage but with cracks on the surface
Type 4 -Like a sausage or snake, smooth and soft
Type 5 -Soft pieces with clear -cut edges ( easy to pass)
Type 6 -Fluffy pieces with ragged edges, a mushy stool
Type 7 -Watery, no solid pieces (entirely liquid)
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 76of 86APPENDIX II. SF-12V2
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 77of 86
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 78of 86
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 79of 86APPENDIX III. EQ-5D-3L QUESTIONNAIRE 
By placing a checkmark in one box in each group below, please indicate which statement s best 
describe y our own healt h state today .
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems wit h self -care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g., work, study, housework, family , or l eisure act ivities)
I have no problems wit h performing my  usual  activi ties 
I have some problems with performing my usual activit ies
I am unable to perform  my usual act ivities
Pain/Discomfort
I have no pain or disco mfort
I have m oderate pain or discomfort
I have extreme pain or disco mfort
Anxiety/Depression
I am not anxious or depresse d
I am moderately  anxi ous or depressed
I am extrem ely anxi ous or depressed
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 80of 86To hel p peopl e say  how good or bad a health state is, we 
have drawn a scale (rather like a thermo meter) on which 
the best state y ou can imagine is marked 100 and the 
worst state is marked 0.
We woul d like you to indicate on thi s scale how good or 
bad y our own heal th is today , in y our opini on.  Please do 
this by drawing a line from  the box below to whichever 
point on the scale indicates how good or bad y our healt h 
state is today .
Your own
health state
today90
80
70
60
50
40
30
20
10100
Worst
imaginable
health state0Best 
imaginable
health state
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 81of 86APPENDIX IV. SHORT -FORM MCGILL PAIN QUE STIONNAIRE -2
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 82of 86APPENDIX V. IRRITABLE BOWEL SYND ROME -SYMPTOM 
SEVERITY SCALE 
IBS- SSS Questionnaire
1. A.  Do y ou currently (in the last month) suffer from abdominal (tummy) pain?
Yes
  No
B.  If yes, how severe is your abdo minal (tummy) pain?  Please indicate a number from 0 
to 10, with 0 meaning “ no pain” and 10 meaning “very severe.”
no pain 0 1 2 3 4 5 6 7 8 9 10 very severe
C.  Pl ease enter the number of ti mes that y ou get the pain every  10 days.  For example, if 
you choose 4 i t means that y ou get pain 4 out of 10 day s.  If y ou get pain every day  
enter 10.
no day s with pain 0 1 2 3 4 5 6 7 8 9 10 10 day s with pain
2.         A.  Do y ou currently suffer fro m abdominal distent ion* (bloat ing, swollen or tight     
tummy )?  *Wom en, pl ease i gnore distent ion related to y our peri od.
  Yes
  No
B.  If yes, how severe is your abdo minal distent ion/tightness?  Pl ease indicate a numb er 
from 0 to 10, wi th 0 meaning “no di stent ion” and 10 meaning “very  severe.”
no distent ion 0 1 2 3 4 5 6 7 8 9 10 very severe
3. How di ssatisfied are y ou wi th your bowel  habi ts?  Please indicate a number fro m 0 to 10, 
with 0 meaning “very  happy” and 10 meaning “very unhappy.”
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 83of 86very happy 0 1 2 3 4 5 6 7 8 9 10 very unhappy
4. Please indicate how much abdo minal pain or discomfort or altered bowel habits are 
affect ing or interfering wit h your life in general.  Please indicate a number from 0 to 10, 
with o meaning “not at all” and 10 meaning “co mpletely.”
not at all 0 1 2 3 4 5 6 7 8 9 10 completely
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc.
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 84of 86 
 
 
 
 
: 19-Oct-2016 15:05
Document Date: 
linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 Octob er 2016
Confidential Page 85of 86 
 
  
   
     
     
 
     
: 19-Oct-2016 15:05

linaclotide Ironwood Pharmaceuticals, Inc
Statistical Analysis Plan: MCP -103-204-SAP-01 04 October 2016
Confidential Page 86of 86 
 
 
: 19-Oct-2016 15:05
Document Date: 
